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Abstract  
 
Quantitative data is an excellent resource in any proteomics study but is essential in many. In 
recent years this area has expanded from relative to absolute quantification with a wide range 
of methods available for absolute quantitative proteomics. In general protein quantification is 
based on either label-mediated or label-free strategies. Common label-mediated approaches 
are isotope dilution strategies, such as AQUA, coupled with mass spectrometry, where analyte 
signal is compared to a stable isotope labelled standard added in known abundance. These 
methods are suited to small-scale studies but increasing demand for large-scale proteome 
quantification exposed the need for alternative quantification methodologies. The QconCAT 
technology, first published in 2005, is a label mediated approach which utilises the principle of 
surrogacy to quantify analyte proteins based on a signature peptide, or peptides, for each 
protein. QconCATs are concatenations of quantotypic peptides for a group of proteins, the 
QconCAT gene is designed in silico and expressed heterologously in E.coli with [13C6]arg and 
[13C6]lys to elicit a stable isotope labelled multiplexed absolute quantification standard.  
In this thesis I describe several developments to the QconCAT production protocol. These 
developments reduce the production time from ~19d, using the initial method, to less than 
7d. Time gains have been made across the whole workflow in the areas of protein expression, 
cell lysis, and product purification. Moreover verification of the QconCAT is delayed until the 
final product is synthesised, made possible by evidence of high quality reproducible 
expression. I explain how these alterations allow for production of several QconCATs in 
parallel, giving added efficiency. The success of the method is demonstrated through the use 
of multiple QconCATs. As a result of this work it is now possible to make at least eight 
QconCATs per week and the rate-limiting step of the quantification workflow has migrated 
from standard preparation to data processing. The final study in this thesis discusses methods 
for accurate quantification of the QconCAT protein and additional applications of QconCATs 
for testing mass spectrometer performance.  
 
 
 
 
Introduction 
   
 
 
 
1. Introduction         8 
1.1 Proteomics         8 
1.2 Protein quantification       9 
1.3 Mass Spectrometry       11 
      The mass spectrometer       11 
      Ionisation        12 
      The mass analyser       15 
1.4 Quantitative techniques utilising mass spectrometry  19 
      Label-free quantitative strategies     19 
      Label mediated quantitative strategies    21 
1.5 QconCAT technology       27 
      Selection of peptides       29 
      Selecting the expression strain     30 
       The T7 expression system      30 
      Quantification with QconCAT     32 
 
 
 
 
 
 
 
 
 
Introduction 
  8 
1. Introduction 
Proteomics is a wide ranging discipline, of which quantitative proteomics is just one aspect; 
QconCAT is one of many methods which can be used for quantification. In order to introduce 
the QconCAT methodology I will discuss some background to proteomics with an emphasis on 
quantitative proteomics. I will also introduce mass spectrometry as the major analysis tool 
most commonly used with QconCAT mediated quantification and discuss the instrumentation 
used.  
1.1 Proteomics 
The proteome (Wilkins et al., 1996) (a) (Wilkins et al., 1996) (b) of an organism describes the 
full complement of proteins expressed from its genetic material under a defined physiological 
and pathophysiological state. Proteomics is the study of the proteome, with an aim to 
characterise every protein expressed and map each protein to its cellular location, function 
and interactions. The field defines identification proteomics, where expressed proteins in a 
particular cell state are identified as present or absent, and quantification proteomics, which 
assesses the amount of protein expressed in a given cell state. This quantification can be given 
relative to other proteins in the cell or sample or as an absolute value. Disciplines such as 
genomics, a study of genes and their function, and transcriptomics, a study of mRNA in a 
genome, work in conjunction with proteomics. However the key advantage of proteomics is 
its ability to look at the changes in protein expression by directly analysing the levels of a 
protein present. The discrepancy between the level of mRNA produced within a cell and the 
resulting level of protein expression was first noticed during a study of human liver proteins 
(Anderson and Seilhamer, 1997), another study into the protein and mRNA in Saccharomyces 
cerevisiae cells (Gygi et al., 1999) revealed a similar discrepancy. More recently a study 
combining transcriptome and proteome analyses on a number of Escherichia coli samples 
revealed that whilst many results from the transcriptome and proteome aligned well there 
were also frequent cases where the values were inconsistent (Yoon et al., 2003). Vogel also 
found this to be true during a study on oxidative stress in Saccharomyces cerevisiae (Vogel et 
al., 2011). This illustrates the importance of proteomics as an alternative to gene-focussed 
studies so that the full picture of cell dynamics can be understood.  
As previously mentioned, there are many facets to proteomics; often analysis of a biological 
sample begins with identification of a target protein or proteins, the proteins can be 
sequenced and characterised to define the structure, post-translational modifications, 
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localisation within the cell, and associated proteins and function. To acquire all of this 
information a wide range of techniques can be employed. The proteins can also be quantified, 
either by relative abundance in changing cell or tissue states, or by absolute abundance in 
copies per cell, and again quantification can employ a variety of methodologies. 
1.2 Protein quantification 
An established and widely used approach to protein quantification is through the use of 
protein binding reagents. Applications range from specific protein targeting to analyses of 
entire proteomes; an atlas of more than 700 antibodies to human proteins has been 
generated, covering tissues in normal and disease states (Uhlen et al., 2005). Two major 
affinity techniques are Enzyme Linked Immunosorbent Assay (ELISA) (Engvall and Perlmann, 
1971) and western blotting (Towbin et al., 1979). More recently the non-affinity based 
technique of mass spectrometry (MS) has also been used for protein quantification.  
An ELISA uses antibodies to probe for specific proteins of interest. A simple ELISA involves the 
immobilisation of a sample, containing the “analyte” protein, onto a surface; a primary 
antibody is then used to bind the analyte. Often a secondary antibody is used to bind the 
primary antibody and this antibody is conjugated to an enzyme. To develop the assay the 
substrate for the enzyme is added, the enzyme catalyses the breakdown of the substrate to a 
product, this is usually detectable by fluorescence or absorbance. If the fluorescence or 
absorbance can be detected quantitatively then the technique can be used to quantify the 
amount of secondary antibody bound and to therefore infer the amount of analyte protein 
bound to the primary antibody. The quantification values obtained can be relative to other 
samples in the assay, or if a “standard” is included in the assay, where a known protein is 
measured in a range of defined amounts, this can be used to create a standard curve, from 
which the absorbance or fluorescence values for the analyte can be read off to give an 
absolute quantification value. This type of assay is specific and sensitive due to the use of 
antibodies which are targeted solely to the protein of interest. The use of an enzyme coupled 
to the secondary antibody allows for possible amplification of signal which increases the 
sensitivity of the assay.  
The western blotting technique also involves the use of antibodies and often detection using 
enzymes, so like ELISA it can be specific and sensitive. For the blot the sample is initially 
separated using SDS-PAGE. The separated proteins in the sample are then transferred to a 
membrane (often nitrocellulose) using an electric field and the membrane is incubated with 
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an antibody to detect the protein of interest. As with ELISA the antibody can be conjugated to 
a radioactive, fluorescent or enzyme marker to allow detection of the bound antibody. When 
an enzyme is used often the product of catalysis will give off a chemiliminescence which can 
either be detected on an x-ray film or with a specialised camera. The resulting image (either 
from the developed film or the image from the camera) will show bands, reflecting where the 
analyte protein was present on the membrane. This image can be analysed using 
densitometry to compare the optical densities (ODs) of the protein bands. If a number of 
samples are present on the blot the relative ODs provide information about the relative 
abundance of the analyte protein between samples. Additionally a standard can be applied in 
a range of known concentrations to the same SDS-PAGE gel as the analyte protein. The ODs 
from the standard can then be used to create a standard curve as with the ELISA technique, 
and the OD of the analyte bands can be used to calculate the amount of analyte in the sample.  
Another affinity technique involves tagging a protein of interest. The tagging of a protein was 
initially used as a purification technique to extract specific proteins and protein complexes 
from a solution. Two plasmids were developed which “tag” an inserted gene with the 
Staphylococcal protein A gene, when the inserted gene is transcribed the protein produced is 
tagged with protein A. The ability of protein A to bind immunoglobulin, particularly 
immunoglobulin G (IgG), is used to remove the protein and tag by interaction with 
immobilised IgG (Uhlen et al., 1983).  The idea was developed to produce TAP-tags – tandem 
affinity purification tags. In this design the tag consisted of protein A, as previously used, 
followed by a TEV protease recognition sequence and then the calmodulin-binding peptide 
(CBP). The TAP-tag was fused to a target protein, and then introduced into cells where the 
target protein-tag conjugate was expressed. The benefit of the dual tag is that there can be a 
two step purification to ensure that the final protein isolated is highly pure and that any 
further analysis of the protein can be as accurate as possible (Rigaut et al., 1999). The TAP-tag 
idea was expanded to quantification through tagging each of the open reading frames (ORFs) 
in S. cerevisiae. A library of S.cerevisiae ORFs was created where, for each ORF, the gene was 
tagged with a TAP and inserted into the chromosome. The method was designed not to alter 
the expression levels of the tagged protein so, after isolation, quantification could be 
completed on each protein in the given cell state. Quantification was performed by 
quantitative western blotting (Ghaemmaghami et al., 2003).  
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1.3 Mass spectrometry  
Mass spectrometry (MS) is a key tool in proteomics; major applications of MS include protein 
identification, peptide or protein sequencing, and importantly for this thesis, protein 
quantification. The diversity of the instrumentation and sample preparation techniques 
available mean that MS can be used for studying a small number of proteins or peptides, up to 
large scale analysis of highly complex samples.  
ELISA and western blotting techniques are typically performed on intact protein. MS can also 
be used to analyse an intact protein but in quantification it is more common to analyse 
peptides resulting from a digested protein or proteins. Within the mass spectrometer peptides 
can be fragmented through collision with an inert gas to give characteristic ion products which 
can be used to sequence the protein, and the use of peptides also gives a wider scope of 
possible methods for quantification. When a peptide is used in a quantitative experiment the 
principle of surrogacy is applied. In proteomics surrogacy presumes that the molar 
quantification of a peptide, arising from a proteolytically digested target protein, can be used 
to directly infer the quantification of that protein. The assumption is made that the peptide 
chosen is present in the same molar amount as the protein itself. The peptide is chosen as a 
“proteotypic” peptide, meaning that it is a sequence unique signature peptide for that 
protein, when the chosen peptide is used for quantification the term “quantotypic” can be 
used, meaning that the peptide is both proteotypic for the protein and also that it is suitable 
for quantification. The criteria which define a peptide as being suitable for quantification will 
be discussed later.  
Typically trypsin is used to digest protein samples; this enzyme is most often chosen as it 
reliably and consistently recognises specific cleavage sites on the C-terminal side of arginine 
(arg) and lysine (lys) residues, except when they are followed by a proline. Tryptic cleavage 
produces predictable arg and lys terminated peptides, with the exception of the C-terminal 
peptide. Once the sample has been fully digested into peptides it is then ready to be analysed.  
THE MASS SPECTROMETER  
A mass spectrometer has three components; an ionisation source, a mass analyser and a 
detector. The role of the ionisation source is to deliver the peptides to the mass analyser in 
the form of charged ions in the gas phase. Once inside the instrument the ions travel through 
a vacuum in the mass analyser, the primary purpose of which is to separate the ions according 
to their mass (m) and charge (z) in the relationship m/z. It is the mass to charge ratio (m/z) of 
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an ion which determines how it will travel through the analyser. Once separated the ions 
collide with the detector, each event is recorded and measured. The output from the detector 
is plotted as a spectrum of ion intensity plotted against m/z. There are a range of ionisation 
techniques which are currently used. The two mostly commonly used in biological sciences, 
which will be discussed here, are both soft ionisation techniques and produce positively 
charged ions by addition of a proton or protons.  
IONISATION  
Matrix Assisted Laser Desorption Ionisation (MALDI), as its name suggests, uses a matrix in 
order to convert analyte (in our case peptides) into positive singly charged ions in the gas 
phase. Matrix ionisation techniques were developed as a way to ionise large intact masses of 
polymers and proteins (Karas and Hillenkamp, 1988) and are extremely effective for peptides. 
The principle of matrix assisted ionisation, (Figure 1) is that the analyte is embedded into 
crystals of a matrix which absorb energy from a laser, in this way energy can be delivered to 
the analyte to induce the non-volatile components into the gas phase without the molecules 
being damaged by extremely high levels of energy; matrix and analyte are ejected into the gas 
phase together (Fitzgerald et al., 1993). It is thought that charge is delivered to the analyte, to 
create ions, via photoexcitation of the matrix, which leads to transfer of protons to the analyte 
molecules (Hillenkamp et al., 1991); in MALDI-MS only singly charged peptide ions are 
produced. Ionisation is variable with MALDI-MS and bias can be seen towards arginine 
terminated peptides due to preferential ionisation of the arginine side chain (Krause et al., 
1999). 
Many different matrices have been screened for their properties as useful compounds for the 
ionisation of a sample for MS (Fitzgerald et al., 1993). We use α-cyano-4-hydroxycinnamic 
acid, this is a crystalline matrix which can be solubilised, mixed with the sample and then 
spotted onto a laser-target plate and allowed to dry before use in the solid state. Some are of 
the opinion that the solid-phase matrices give bias to an analysis (Tholey and Heinzle, 2006). It 
has been argued that regardless of how well combined the matrix and sample are, “hot spots” 
will form when the matrix dries; these are places within the overall sample spot that provide 
much more intense spectra, other areas of the spot may give much weaker spectra and so 
reproducibility between analyses is called into question. For this reason liquid matrices are 
sometimes considered more suitable. Liquid matrices are made by mixing the crystalline 
matrix of choice with an organic solvent, such as pyridine. Due to the fact that the liquid 
contains the same matrix material as in crystalline matrices the ionization of analyte is 
Introduction 
  13 
thought to occur in much the same way, however it has been reported that the homogeneity 
of the spot is increased using liquid matrices, something which is beneficial for reproducibility 
of data.  
 
Figure 1| MALDI ionisation of peptides. Energy from laser excitation of the matrix induces 
expulsion of matrix and analyte peptides into the gas phase. Protons are transferred to the 
peptides and matrix ions are lost to create positively charged ions which progress into the 
mass analyser  
Whilst MALDI ionisation is effective and has the benefit of being relatively tolerant to 
contaminants in the sample, it has been observed that the response factor of a peptide can be 
unpredictable with MALDI and equimolar peptides in a sample can give radically different ion 
signals such that one peptide might not even be detected. Couto et al. conducted an 
investigation into the effects of using different proteases to digest the sample. They found 
that changes in the positioning of a basic residue within a peptide, dictated by the location of 
the enzymatic cleavage, greatly altered the response of an ion in MALDI (Couto, 2011). 
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An alternative to MALDI ionisation is Electrospray Ionisation (ESI) (Figure 2). The end result of 
ESI is the same as MALDI; positively charged peptide ions are ejected into the gas phase and 
directed into the mass analyser. However the way in which the ions are created is very 
different and as a result ESI can produce ions with multiple positive charge states.  
 
Figure 2| ESI ionisation of peptides. The sample is positively charged by electric current, a 
fine spray of charged droplets are ejected from the tip. The solvent evaporates until the 
Rayleigh limit is reached, whereby the droplets separate out into smaller droplets, this cycle 
repeats until charged ions remain, these move through the negatively charged cone into the 
mass analyser.    
The sample, a solution of peptides, is delivered via a capillary tube to a tip from which the 
sample is sprayed into the mass spectrometer. In the case of positive ionisation an electric 
field, delivered to the tip, positively charges the liquid as it flows through. As the multiply 
charged liquid exits the tip, Coulomb (C) electric charge forces cause droplets to form which 
repel each other and disperse, creating a spray. The solvent carrying the peptides evaporates 
and the charge density on the droplet increases until the “Rayleigh limit” is reached. This limit 
is defined as the point where the charge on the surface of the droplet (C) reaches a density 
where the repulsion between charges is equal to the surface tension of the droplet; at this 
point the droplet separates out into smaller droplets. This cycle repeats for the smaller 
droplets and eventually leaves peptide ions with multiple positive charges which pass through 
a negatively charged sample cone and can be analysed in the mass spectrometer (Fenn et al., 
1989; Cech and Enke, 2001).  
Due to the fact that ESI is compatible with liquid flow a significant proportion of MS analyses 
that use ESI as their ionisation technique are preceded by a Liquid Chromatography (LC) step 
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to reduce the complexity of the sample. This step is not part of the MS analysis but is often 
used in conjunction with MS to increase the resolution of the analysis. The sample to be 
analysed is taken up into an LC system (or nano-HPLC if very small volumes are being used). 
Depending on the technology an autosampler can be used to inject samples from pre-defined 
vial locations. The sample is then loaded onto a column; there are various columns which can 
be used which separate out peptides based on different properties, one example is a reverse 
phase column which separates out peptides based on their hydrophobicity. The elution from 
the column is pumped through capillary to the ESI source where it can be sprayed into the 
mass spectrometer. The elution time from the column becomes a factor in the MS analysis 
and adds another dimension to the MS spectra; peptide ions elute into the mass spectrometer 
according to their retention time (RT) so the m/z, intensity and RT of a peptide ion is 
measured.  
THE MASS ANALYSER  
Ions are separated according to their m/z in the mass analyser. The instruments used in this 
study have Time of Flight (TOF) mass analysers.  The m/z value for an ion is based on the time 
it takes for the ions to travel along a TOF tube of specified length. In the simplest TOF 
instruments the ions enter the instrument in the gas phase and are accelerated by an electric 
field. This acceleration means that ions of the same charge should have the same kinetic 
energy as they enter the flight tube. After acceleration the ions travel along a linear tube, 
which is free from any electric field, until they hit the detector. The time taken for this flight is 
recorded and can be used to calculate the m/z of a peptide.  
The longer the flight tube the greater the separation, or resolution, of the ions, therefore the 
TOF tube is ideally as long as possible. The tube is generally not longer than 1-2 meters, due to 
space restrictions in laboratories; however a way to increase the length of the flight without 
increasing the size of the instrument is to reflect the ions back along a different trajectory 
using ion mirrors (reflectron), therefore doubling the length of the flight. This increase in flight 
distance increases the separation between the ions and therefore improves resolution in the 
spectrum; this is termed reflectron TOF. Two instruments used in this study - the WatersTM 
MALDI-TOF and the Bruker Ultraflex MALDI-TOF, both use single reflectron TOF. The WatersTM 
Synapt G1 and WatersTM Synapt G2 and are also used in this study, these instruments have a 
TOF system which can be used in reflectron “V” mode with a single ion reflection or in “W” 
mode with three reflections to further increase the resolution.  
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In the case of the Synapt G1 and G2 their mass analysers differ to the standard TOF seen with 
the MALDI-TOF instruments. In these two instruments there is a quadrupole (Q) mass analyser 
placed before the TOF, the instruments are therefore described as being Q-TOF tandem mass 
spectrometers. A schematic of the G2 can be seen in Figure 3.  The ions enter the mass 
spectrometer and are guided through to the quadrupole. The quadrupole is made up of four 
rods which conduct electric current; variations in the voltage applied to the rods will alter the 
field around them. As an ion enters the quadrupole the electric field can be used to conduct 
the ion through to the TOF, or the ion could be lost by altering the flight path in the electric 
field, resulting in a collision with one of the rods. The quadrupole can therefore be used to 
simply transmit ions through to the TOF or to select specific ions according to their m/z. 
Use of the quadrupole to select specific ions is often coupled with another feature of the mass 
analyser in the Synapt instruments – the collision cell.  In the G2 this is made up of the trap, 
ion mobility and transfer regions that can be seen on the schematic. The collision cell is 
continuously active however in normal MS mode ions simply pass through to the TOF as the 
collision cell is in a low energy state. When the collision cell is active it switches to high energy, 
and analyte ions are bombarded with atoms of an inert gas, this fragments the peptide (in 
terms of fragmentation the peptide is referred to as the precursor ion) into smaller fragments 
(referred to as the product ions) which can then be separated in the TOF and measured by the 
detector. This fragmentation process by collision induced dissociation (CID) is a form of 
MS/MS. There are two different types of MS/MS, data dependant and data independent. In 
data dependant mode ions are monitored and periodically the top 3 ions, or ions over a 
certain intensity threshold, are selected by the quadrupole and the instrument then switches 
to high energy mode and fragments the peptides chosen. The Synapt instruments are also 
able to perform data independent MS/MS (termed MSE). In MSE all of the ions present in the 
quadrupole are fragmented without selection of any kind. The purpose of MS/MS is to 
fragment the peptide ions to provide more detailed structural information about the peptide.  
A similar feature can be used on the Bruker Ultraflex MALDI-TOF instrument, termed 
“TOF/TOF”. In MS/MS the range of fragments that can be produced can be characterised 
under the Biemann nomenclature (Johnson, 1988), we mainly use b and y  ions as these are 
fragments at the peptide bond and are usually most abundant. An additional feature of the 
Synapt G2 is the ion mobility separation feature, which WatersTM term the “HDMS” mode. This 
delivers increased separation of ions in the MS mode; ions are separated according to their 
cross-sectional area using a Travelling Wave potential. This increases the temporal separation 
between different m/z ions and therefore increases resolution in the mass spectrum.  
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A method which utilises the selective abilities of the quadrupole and MS/MS fragmentation is 
Selected Reaction Monitoring (SRM). With SRM a particular ion in selected by the user, this 
ion is isolated and then fragmented and the product fragments recorded. The instrument will 
have the capability to monitor a specific product ion as well as the precursor; the precursor-
product ion pair is a “transition”. The instrument used determines whether the analysis can be 
termed an SRM or a pseudo-SRM. A true SRM is performed on a triple-quadrupole MS 
instrument; the mass analyser in a triple-quadrupole is made up of three quadrupoles that 1) 
select the precursor peptide ion to fragment 2) fragment the ion and 3) select product ions for 
the detector. In the case of a Q-TOF instrument the quadrupole is used to select the precursor 
ion, however once the ions are fragmented the lack of a second quadrupole means that 
product ions cannot be specifically selected, so all of the product ions are monitored; this is a 
“pseudo SRM”.  
Multiple SRMs can be used in a single MS analysis. Multiple SRMs can be referred to as 
Multiple Reaction Monitoring (MRM), although the term is less often used and SRM is 
commonly used to describe MRM experiments. The benefit to SRM or MRM is that the user 
selects the precursor ions to be monitored and these are programmed into the method prior 
to the analysis. MRM does not use Top3 or intensity threshold criteria to select ions for 
fragmentation, therefore the peptide of interest is always selected for MS/MS fragmentation. 
In MS based proteomic analyses a common obstacle is the limit of detection (LOD); this is the 
limit at which an ion can be detected and reliably distinguished from the background “noise”. 
The LOD therefore becomes more of a challenge when analysing peptides in a complex 
background (Gallien et al., 2011). SRM can help to pull the target peptide out of the 
background and acquire fragmentation data on lower abundance peptides, and in this way it 
can “dig deeper” into the proteome. SRM is well suited for use in quantification studies across 
a large dynamic range (Picotti et al., 2009) however the method does require initial analyses, 
selection of the best transitions and correction of collision energies before it can be run 
(Campbell et al., 2011), this means it can be a lengthy process. Picotti et. al. (Picotti et al., 
2010) have presented a higher-throughput method for SRM where they use proteomic data 
sets to select potential SRMs for target proteins and then synthesise all potential peptides 
using Spot Synthesis. The potential peptides are screened using SRM based MS assays and the 
most appropriate transitions are selected.  Their workflow could make SRM more accessible 
and applicable to large scale studies. 
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1.4 Quantitative techniques utilising mass spectrometry  
In a quantification experiment, as mentioned previously with ELISA and western blotting, the 
quantification can be relative, comparing the abundance of protein(s) between different cell 
states and monitoring changes in abundance under certain stimuli; or absolute, where analyte 
protein(s) are quantified to the level of copies per cell. The approaches taken for relative or 
absolute quantification can be classed according to whether the method is label-free, relying 
on MS data processing and in some cases unlabelled internal standards, or label-mediated, 
where a chemically or metabolically incorporated label is used to differentiate between 
standard and analyte (Figure 4).   
LABEL-FREE QUANTITATIVE STRATEGIES 
Initially, label-free quantification strategies were solely focused on relative quantification 
values. Techniques such as spectral counting can be used to estimate the relative abundance 
of a protein (Liu et al., 2004); this approach involves counting the number of MS/MS spectra 
acquired for a peptide. It was discovered that the number of spectra acquired directly 
correlated to the abundance of that peptide and therefore the abundance of the parent 
protein in the sample. However spectral counting can become less reliable when looking at 
lower abundance proteins with fewer spectral counts (Lundgren et al., 2010). One of the more 
simple relative quantification methods available is Accurate Mass Retention Time (AMRT) 
(Silva et al., 2005). This method of quantification is based on the peptide ion signal intensity in 
the MS spectrum; by using the accurate mass measurement and corresponding retention time 
for a peptide signal, the ion intensity of the same peptide can be compared across samples 
and the relative abundance of the parent protein inferred from the intensity ratios. This 
technique relies on robust and reproducible sample preparation and LC-MS performance and 
can therefore be subject to inaccuracies.  
Similar to AMRT, other quantitative techniques have been established which also utilise the 
peptide ion signal intensity or signal area. There are a number of different Area Under the 
Curve (AUC) label-free methodologies which compare the signal area and use this to infer 
quantification. In initial development tryptic digests of a range of concentrations of myoglobin 
were analysed using MS. The concentrations of myoglobin prior to digestion ranged from 
10fmol to 100pmol and it was discovered that over this range the concentration of the 
myoglobin starting protein and the sum peak areas in the MS spectrum, for five selected 
peptides, showed a linear correlation (r2=0.991) (Chelius and Bondarenko, 2002). In a later 
study, the molar range was decreased to cover 10fmol to 1000fmol for cytochrome c digest 
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and the target peptide peak intensities were normalized to four common internal standards, 
this was found to give an improved r2=0.9978 (Bondarenko et al., 2002).  
 
 
Figure 4|Quantitative methods. Summary diagram giving an overview of quantitative 
methods applicable for use with mass spectrometry, the methods are divided into relative and 
absolute quantification strategies and further subdivided according to whether label is used, 
and how the label is introduced.  
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Relative quantification data can give a broad overview of the expression changes within a cell 
and it is often more simple to set up a relative quantification experiment. However, whilst 
relative quantification is all that is necessary for many applications, if individual proteins 
within the same sample need to be compared to one another, or a more accurate view of the 
scale of an abundance change and its effects is required, absolute quantification is necessary 
(Bronstrup, 2004). More recently AUC label-free quantification has been developed to an 
absolute quantification strategy (Silva et al., 2006). In this approach the top three most 
intense tryptic peptides for the protein of interest are used. A single unlabelled standard is 
also included in the assay, which can be added to the sample, in a known amount, prior to 
digestion and co-digested with the analyte proteins. After the sample is analysed using MS an 
average signal response for the top three peptides from the standard is taken and used to 
calculate the “universal signal response factor”, which is measured in counts/mol protein. The 
absolute value of each of the proteins in the sample can then be calculated by dividing the 
average signal response, for the top three peptides for that protein, by the universal signal 
response factor. It was also demonstrated that this method was applicable to simple and 
complex samples.  
Quantitative MS based proteomics, especially label-free quantification, relies heavily on the 
software used to analyse the data. There is a huge variety of software available for different 
applications. In this study ProteinLynx Global Server (PLGS) software from WatersTM is used, 
this performs label-free quantification based on the “top3” principle and comparison to a 
spiked in protein digest of known concentration acting as a standard. Another example 
software is MaxQuant, which started out as software for label-mediated SILAC quantification 
(Cox and Mann, 2008) but now also includes label-free quantification (Luber et al., 2010).  
LABEL-MEDIATED QUANTITATIVE STRATEGIES 
In general, for label-mediated quantification, stable-isotope labels are used. The benefit of 
these isotopes is that they introduce a mass shift in the tagged peptide, distinguishing it from 
the untagged peptides but the tagged and untagged peptides still show similar behaviour; 
they have the same retention time, efficiency of ionisation and during MS/MS produce the 
same ion fragments (Pan et al., 2009). They are also preferred over radioactive isotopes as 
they do not require stringent safe handling procedures and do not rapidly decay. There are 
many different stable isotopes available; common forms used are 13C, 15N, 2H and 18O. In order 
to have clear separation between tagged and untagged peptides it is helpful to have a mass 
shift of 3/4Da to reduce overlapping peaks affecting the quantification (Ong and Mann, 2005). 
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For relative quantification with stable isotope labels, the samples are differentially labelled to 
distinguish between them, they are then digested and analysed in parallel using MS. Analysis 
of the standard and analyte produces pairs of peaks on a spectrum – an unlabelled lower m/z 
peak and the higher m/z labelled peak. The intensity ratio between the two peaks echoes any 
changes in expression of that protein between the two cell states (Gouw et al., 2010). For 
absolute label-mediated quantification the same principle of comparing standard and analyte 
peaks is used but an accurately quantified standard is added to give an absolute value to the 
quantification.  
With the standard and analyte requiring differential labelling a consideration for label-
mediated quantification is the level of error which could be introduced through the individual 
treatment of the samples. Ideally they should be combined as early on as possible in the 
workflow to minimise variation in treatment (Figure 5). If two cultures are differentially 
labelled they can be combined prior to cell lysis giving the greatest minimisation of variance. If 
this is not possible the next point to combine is prior to digestion; this still minimises variation 
in digestion efficiency and errors in pipetting. A greater level of variation is introduced if the 
peptides are pooled post-digestion.  
 
 
 
 
 
 
 
 
Figure 5| Stages in the quantitative workflow where samples can be combined. A and B 
represent samples to be analysed, ideally A and B would be combined as early on in the 
workflow as possible, prior to cell lysis. Alternatively proteins can be combined prior to 
digestion or, less desirably, prior to MS analysis. The greatest level of variance is introduced if 
samples are not co-analysed.   
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Label can be introduced to the standard, or to differentially labelled samples, by chemical or 
metabolic means. Chemical labelling involves tagging the target proteins prior to digestion, 
the target peptides post-digestion or using a standard synthesised in a cell-free environment. 
Isotope-Coded Protein Label (ICPL) is a chemical labelling method for relative quantification of 
proteins (Schmidt et al., 2005). Two samples can be differentially labelled after cell lysis; the 
ICPL reagent is either a deuterium containing (heavy) tag or is deuterium free (light tag). The 
proteins are tagged at free amino groups and can then be combined for digestion. Signal 
intensity from the light and heavy tagged peptides can be used to infer relative quantification. 
Another labelling method for relative quantification is ICAT, where the protein is again 
targeted for tagging, however unlike ICPL, in ICAT it is the cysteine residues that are tagged. 
The tag can be deuterated to elicit an isotopically labelled reagent, and in a similar way to ICPL 
two samples can be differentially labelled with the light or heavy forms of the reagent. The 
samples can then be combined for digestion. The reagent is restrictive in that it only tags 
cysteine containing peptides so not all of the peptides are suitable for quantitative analysis. 
However the reagent contains a biotin molecule so post-digestion the tagged peptides can be 
isolated from the solution using avidin. Comparison of the heavy and light peptide pairs in an 
MS spectrum is used to infer relative quantification (Gygi et al., 1999). The benefit of both 
ICPL and ICAT is that the proteins are tagged so co-digestion is possible, which helps to reduce 
variation in the treatment of samples and increases the accuracy of quantification.  
For targeting of peptides, rather than proteins, Isobaric Tags for Relative and Absolute 
Quantification (iTRAQ) (Ross et al., 2004) reagents are commonly used. The tags bind free 
amines at the N-terminus of the peptide and on lysine side chains. Every peptide in a digest is 
labelled, meaning that every peptide can be used as a standard or basis for comparison for 
relative quantification. Initially there were just four reagents however this has now increased 
to eight. Each reagent could be used to tag a different sample set, for example eight different 
growth conditions or disease states could be analysed and compared simultaneously. The 
reagents are isobaric so they do not differ in mass, therefore when the tagged peptides are 
analysed using MS there is no mass shift seen in the spectrum; however each of the four or 
eight tags releases a different “reporter ion” in an MS/MS spectrum. The intensity of the 
reporter ion can be used to relatively quantify the parent peptide and therefore the protein. 
iTRAQ is commonly used as a relative quantification technique, however it can be made 
absolutely quantitative with the use of accurately quantified, and subsequently tagged, 
surrogate peptides, at least one peptide per protein in the analyte mix would need a 
quantified surrogate. iTRAQ is an excellent technique to study multiple samples in parallel. 
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The method does call for extremely careful sample preparation, there are pitfalls which can 
compromise the accuracy of the data, such as the reactivity of the tags with amine groups, 
meaning that amine containing buffers such as Tris and ammonium bicarbonate cannot be 
used, and adding the tags to a peptide solution at low pH can cause the tags to react with 
tyrosine residues (Unwin, 2010).  Additionally as the tag is applied to peptides it is introduced 
later in the protocol, which allows for a greater level of error due to variance between 
treatment of samples. A significant number of chemical labelling techniques tag peptides and 
hence they all have an increased propensity for variation in samples. However, with iTRAQ the 
late introduction of the tag can also be useful in some cases where in vivo labelling of the 
analyte is not possible due to the cost or scale of the labelling, for instance in the analysis of 
human tissue. As a variation to iTRAQ reagents there are also mTRAQ reagents available 
(Applied Biosystems, Inc., Foster City, CA) which work on a similar principle to iTRAQ but 
introduce a mass-shift with the tag (DeSouza et al., 2008). There are fewer channels available 
with the mTRAQ tag – just three including an “unlabelled” tag so there is less scope for 
comparison between multiple cell states simultaneously. As with iTRAQ, the mTRAQ reagents 
can be used for relative quantification, or absolute if a standard is used as one of the tagged 
samples.   
Another tagging technique is Tandem Mass Tags (TMT), which again can be used to 
differentially label two samples (Thompson et al., 2003). Similarly to iTRAQ, the tags are 
designed to generate a reporter ion in an MS/MS spectrum which can be used for 
quantification. A benefit of the TMTs is that the reactive functionality can be altered to bind to 
different groups depending on the needs of the user.  
Chemical labelling does not always involve tagging with a reagent. Amongst other labelling 
techniques is 18O labelling. Trypsin is used to digest the analyte protein(s) in a buffer 
containing enriched 18O water, which is incorporated into the peptides as the enzyme 
hydrolyses the peptide bond.  Two 18O molecules are included in each peptide, one at each 
terminus, which gives a 4Da mass shift (Heller et al., 2003). This method is typically used for 
relative quantification, however if a standard protein of known abundance was 18O labelled 
before combining the standard and analyte peptides, then absolute quantification could be 
possible. The label in this method is introduced at a later stage in the protocol, so there is a 
greater chance for error. However in a similar way to iTRAQ this method is widely applicable 
to studies where the samples cannot be SILAC or otherwise labelled. As a final example of 
chemical labelling of peptides, dimethyl labelling can be used (Hsu et al., 2003), formaldehyde 
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is used to label the N-terminus and an amino group on lysine residues to differentially label a 
set of peptides.  
Rather than labelling analyte proteins with reagents, labelled standards can be synthesised for 
quantification of target proteins. These standards can be produced in stable isotope labelled 
form in a cell-free environment and can subsequently be accurately quantified to enable them 
for use for absolute protein quantification. Protein Standard Absolute Quantification (PSAQ) is 
an example of a chemically synthesised protein standard which can be used for absolute 
quantification (Brun et al., 2007). The full length protein can be combined and co-digested 
with the analyte protein, the resulting peptides can all be used for quantification of the target, 
giving greater reliability to the method as co-digestion with the analyte minimises variation in 
sample treatment. However, for each target protein a standard needs to be synthesised so 
this method does not lend itself to large scale quantification. Absolute Quantification 
peptides, or AQUA peptides (Gerber et al., 2003) are chemically synthesised peptides that are 
stable isotope labelled and accurately quantified. They can be spiked into a sample in known 
abundance before mass spectrometric analysis in order to quantify the corresponding analyte 
peptide and therefore the analyte protein. Whilst quantification of the target protein is 
possible from a single standard peptide, a more reliable quantification value would be 
obtained from multiple peptides, in this way AQUA could be less reliable than PSAQ unless 
multiple peptides were synthesised for each protein. The peptides are also combined with the 
sample later on in the analysis as they do not need to be co-digested, and this has the 
potential to introduce variation. Production of AQUA peptides can be expensive, especially if a 
large scale study is considered. However a benefit to the chemical synthesis of the peptides is 
that post-translational modifications can be added to the peptide if desired (Kettenbach et al., 
2011).  
As previously mentioned, to reduce error in quantification the analyte and standard samples 
should be combined as early on as possible in the protocol. In order to do this the label needs 
to be introduced as early as possible and metabolic labelling in vivo rather than chemical 
labelling in vitro can allow for early introduction of the label (Gouw et al., 2010). As with 
chemical labelling, metabolic labelling can be performed with a number of different isotopes 
and in different forms. For algae, bacteria or yeast the growth media can be supplemented 
with a stable isotope such as 13C and 15N. Commonly 15N can be supplied in the form of 
ammonium chloride and 13C can be supplied in the form of glucose (Uphaus et al., 1967; Oda 
et al., 1999). The resulting proteins will be labelled with varying mass shifts depending on the 
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length of the protein; this can make processing more difficult. The labelled culture can be 
compared to an unlabelled culture for relative quantification; as the proteins are labelled in 
vivo the cells can be combined prior to cell lysis to minimise variation.  
A widely used metabolic labelling strategy is Stable Isotope Labelling by Amino Acids in Cell 
Culture (SILAC). SILAC is an umbrella term which covers a wide range of techniques. Initially 
SILAC defined the labelling of a cell culture with a stable isotope labelled amino acid such as 
deuterated leucine (Leu-d3), a labelled culture and a non-labelled culture could be combined 
and the relative protein abundances quantified using MS by comparing the intensity of 
labelled and unlabelled peptide ion peaks (Ong et al., 2002). This has the benefit of being able 
to compare an entire proteome from one labelled culture. Arginine and lysine are commonly 
used in SILAC experiments along with trypsin as the enzyme of choice. Trypsin reliably cleaves 
protein after Arg or Lys residues and so leaves peptides with a consistent single heavy amino 
acid at the C-terminus of the peptide, releasing a labelled peptide which will show a 
predictable m/z shift in a mass spectrum. However there are other possible amino acids and 
isotopes which can be used according to the particular needs of the study. With SILAC the 
label is introduced early in the workflow and so the analyte and standard can be mixed prior 
to digestion, this limits variation in digestion efficiency. As an alternative method SILAC has 
also been used to generate a heavy reference proteome which can then be “spiked in” to 
several light analyte samples for relative quantification (Geiger et al., 2011). SILAC has recently 
been used to describe the metabolic labelling of larger invertebrates such as Caenorhabditis 
elegans up to mammals such as mice, additionally “absolute SILAC” has been developed.  
It has become increasingly common to use labelling of larger organisms for relative 
quantification (Gouw et al., 2010). As these organisms are not grown in culture the method of 
introduction of the label can be more complex. In the labelling of mice a synthetic, usually 
semi-synthetic, diet can be used which contains the stable isotope labelled amino acids. The 
end result of labelling is typically 50% which, if taken into account in analysis and data 
processing, still allows for effective quantification. For other organisms a two-step labelling 
technique can be used; C.elegans has been labelled in this way. This two step technique 
involves initially labelling E.coli with 15N using ammonium chloride as the 15N source (Krijgsveld 
et al., 2003) or a supplemented labelled amino acid, lysine, (Fredens et al., 2011)) and 
subsequently using the labelled E.coli as the food source for C. elegans. Quantification of 
proteins extracted from model labelled organisms such as C. elegans is relative.  
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For absolute quantification a SILAC labelled standard can be produced in vivo which is then 
spiked in with the analyte prior to digestion (Hanke et al., 2008). The recombinantly expressed 
proteins are purified and accurately quantified before co-digestion, so comparison between 
the standard and analyte peptide signal intensities can be used to absolutely quantify the 
target protein. This method has the advantage of absolute quantification, however it is limited 
by the time and costs of producing multiple labelled protein standards.   
When selecting a label-mediated quantification strategy the decision has to be made between 
relative and absolute quantification. If absolute quantification is to be used the two major 
classes of method use peptide or protein standards. Whilst the proteins standards offer the 
benefit of co-digestion with the analyte and a greater number of quantification peptides they 
can take a longer time to synthesise for each target protein and every peptide is not necessary 
for quantification of the analyte. A compromise between the two could be QconCAT.  
1.5 QconCAT technology  
 
A QconCAT is a concatenation of proteotypic peptides for a set of proteins of interest. A 
QconCAT is assembled as a protein and can be co-digested with the analyte to reduce 
variability. The benefit over other protein standards is that tryptic peptides for multiple 
proteins are included in a single QconCAT construct, so quantification can be multiplexed. 
QconCAT technology utilises the principle of surrogacy, which has been discussed previously. 
A QconCAT is a protein which is made up of carefully selected tryptic peptides; Figure 6 is an 
overview of the QconCAT design process preparation and use. The design of the construct 
occurs in silico; proteins of interest are selected and peptides from each are chosen, using a 
number of different criteria. The peptides are concatenated into a protein sequence, and 
certain peptides are added to the sequence for purification or quantification of the construct. 
Finally a gene is designed, which codes for the entire construct and this is inserted into a 
plasmid vector (Beynon et al., 2005; Pratt et al., 2006). The plasmid is inserted into E.coli and 
the QconCAT protein is expressed in media containing stable isotope labelled amino acids. The 
construct is purified from E.coli cell lysate using nickel affinity purification before co-digestion 
with the analyte proteins and MS analysis.  
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Figure 6 | QconCAT overview of production and use. Quantotypic peptides are selected from 
proteins of interest and assembled into a concatenation. Additional peptides are included in 
the sequence before the gene is synthesised and inserted into a plasmid vector.  The QconCAT 
is expressed, purified and quantified before co-digestion with analyte proteins and MS 
analysis for quantification of analyte proteins.  
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SELECTION OF PEPTIDES 
The terms proteotypic and quantotypic (section 2.3) are regularly used to describe peptides 
which are suitable, under a number of criteria, for analysis and quantification of proteins. 
Computational tools have been developed to predict proteotypic peptides for a given protein, 
especially the detectability of the peptide in an LC-MS/MS analysis (Mallick et al., 2007; Li et 
al., 2010). Properties of the amino acid residues affect the detectability of a peptide and it has 
become increasingly evident that a proteotypic peptide is not necessarily a quantotypic 
peptide; specific criteria need to be met for a peptide to be suitable for use in a quantification 
experiment (Brownridge et al., 2011) such as:  
 Charge on amino acid side chains 
 Hydrophobicity of amino acid side chains 
 Amino acid side chain length 
 Peptide structure 
 Must have a unique m/z value that does not overlap with another peptide in the 
analysis 
 Ionisable to be able to be detected 
 Must be reproducibly observed 
 Avoid post-translational modification 
 Avoid methionine residues 
Post translational modification are avoided due to the fact that the peptide can exist in the 
modified and unmodified form in the analysis; the presence of both forms would split the 
signal for that peptide and so give a bias towards a weak quantification. Similarly methionine 
is avoided as it can be oxidised and again this would split the signal giving poor quality 
quantification.   
Digestion efficiency is extremely important in a quantification experiment; for the 
quantification to be reliable all of the peptides, analyte and standard, must be released from 
the parent proteins. A problem which is often seen in proteomics is “missed cleavage”, where 
a digestion site, for example a tryptic cleavage site after an Arg or Lys residue, is not cleaved 
or only partially cleaved. This results in incomplete release of the peptide, and if that 
particular peptide is being used for quantification the value calculated with be biased. 
Recently prediction tools such as CONSeQuence include information derived from a missed 
cleavage predictor to avoid peptides that might not be completely cleaved (Eyers et al., 2011). 
When the QconCAT method was first published in 2005 (Beynon et al., 2005), then termed 
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“QCAT”, the construct contained a single representative “Q-peptide” for each protein which 
was selected using much fewer criteria than are currently used. The QconCAT protocol has 
now been developed to include at least two Q-peptides per protein for more accurate 
quantification and CONSeQuence is regularly used to select appropriate quantotypic peptides. 
SELECTING THE EXPRESSION STRAIN 
For the last 40 years E.coli has been used as a tool in molecular biology. It lends itself well to 
this task as E.coli culture has a robust and high growth rate and cultures can be grown 
relatively cheaply (Baneyx, 1999; Wang et al., 2010). It is also an extremely well characterised 
organism; the scientific community has accumulated a wealth of information on E.coli genes 
and proteins. Although the E.coli genome was not the first to be completely sequenced, it was 
one of the earliest with the complete genome sequence of K-12 published in 1997(Blattner et 
al., 1997) and the complete BL21 (DE3) sequence following in 2009 (Jeong et al., 2009). There 
are many different E.coli mutants available that are knockout strains for genes coding proteins 
such as proteases; crucially E.coli tolerates mutations well. The BL21 (DE3) strain has been 
used for many years for expression of recombinant proteins, the strain which we use for 
QconCAT expression is BL21 (λDE3). This BL21 strain is deficient in both lon protease 
(regulates gene expression by degradation of regulatory proteins such as transcription 
regulators) and ompT protease (protease located in the outer membrane) making it a more 
stable environment for recombinant proteins. The λDE3 indicates that the E.coli contains λDE3 
prophage DNA, this means that the E.coli strain contains the T7 RNA polymerase gene and this 
is used during recombinant protein expression.  
THE T7 EXPRESSION SYSTEM  
Once the QconCAT gene has been synthesised it is inserted into the pET-21a plasmid vector. 
This vector is chosen for two key features; firstly the vector has a selectable marker for 
ampicillin resistance, meaning that E.coli cells which successfully take up the vector 
(transformed) will be resistant to ampicillin antibiotic, and growth of transformed cells on 
ampicillin-containing agar plates allows selection of only the correctly transformed cells.  The 
exact mechanisms of transformation are not known; the use of CaCl2 and heat shock aid 
transformation and it is thought that the calcium ions’ positive charge may shield the negative 
charge on the DNA, or on the cell surface membrane (Watson, 2004) whilst the heat shock 
may induce pores in the membrane which would allow passage of the shielded DNA molecule 
into the cell. The transformation process is inefficient with only a small percentage of cells 
taking up the plasmid vector. The antibiotic selection of successfully transformed cells is 
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therefore very important. Secondly the inserted gene is placed under the control of a T7 
promoter which means that expression of the gene can be controlled using the T7 expression 
system.    
The T7 expression system, first used by Studier and Moffatt (Studier and Moffatt, 1986), is 
based on utilising the bacteriophage T7 RNA polymerase. The BL21 (λDE3) host contains the 
T7 RNA polymerase gene inserted into the bacterial chromosome under the control of the lac 
operon which keeps the polymerase from being transcribed under normal cell conditions. This 
polymerase is highly selective for the T7 promoter, which is not usually present in an E.coli 
cell. The pET21a vector, containing the T7 promoter, is transformed into the cell. After 
antibiotic selection of transformed colonies, the cells are cultured and once a suitable cell 
density is reached, isopropyl β-D-1-thiogalactopyranoside (IPTG) is added. The repressed 
lacUV5 promoter in the lac operon prevents the T7 polymerase from being transcribed, 
however IPTG is a synthetic analogue of allolactose (the natural activator for the lac operon) 
and its presence within the cell switches off the lac repressor, activating the lacUV5 promoter 
and allowing transcription of the T7 polymerase to occur (Lewis et al., 1996). The newly 
synthesised T7 RNA polymerase recognises the T7 promoter on the plasmid vector and 
transcribes the QconCAT gene linked to it.  
Another method has been developed to induce expression of a recombinant protein by 
autoinduction (Studier, 2005). This also uses the T7 expression system but does not require 
the addition of IPTG. BL21 (DE3) cells containing a recombinant gene on a pET21a plasmid 
vector are grown in autoinduction media specifically designed to use allolactose as the 
inducer. The media contains lactose and a restricted amount of glucose. The glucose is 
designed to sustain the culture only until it reaches a suitable density for induction. The 
presence of glucose prevents T7 induction by lactose as the cells use glucose preferentially as 
a carbon source. Once the glucose has been depleted the cells begin to use lactose as their 
carbon source. As the cells begin to metabolise lactose the metabolite allolactose is produced. 
Under normal cell conditions this would bind to the lac repressor, allowing transcription of the 
genes in the lac operon and so facilitating lactose metabolism. In a BL21 (DE3) cell the 
presence of allolactose removes the repression of the T7 lac promoter and so induces 
expression of the T7 RNA polymerase, leading to expression of the inserted gene on the 
pET21a vector. This method of induction can be extremely useful as the optical density of the 
culture does not need to be monitored to induce expression so a culture can be left to induce 
overnight.  
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QUANTIFICATION WITH QCONCAT  
The QconCAT construct is typically expressed in minimal media containing stable isotope 
labelled arginine and lysine. The “heavy” labelled QconCAT is then purified using nickel affinity 
chromatography by virtue of the hexahistidine tag and the purified protein can be quantified 
using a protein assay. The QconCAT is added, in a known amount, to the analyte proteins and 
co-digested with trypsin to elicit peptide pairs for quantification – a heavy peptide from the 
QconCAT and a “light” peptide from the analyte. The digest is analysed using MS and the 
intensity ratios between heavy and light peak pairs can be used to quantify the target 
proteins. Quantification with QconCAT is applicable to all ionisation techniques and mass 
spectrometers including ESI-TOF and MALDI-TOF MS  (Rivers et al., 2007). Quantification 
experiments using QconCAT often involve MRM assays as a more targeted approach; SRMs 
are designed for each of the QconCAT transitions and its analyte counterpart.  
A protein assay is commonly used to quantify the standard, however an alternative method 
for quantification of the QconCAT standard has been developed that involves the use of a 
quantification peptide that can be included in each QconCAT construct. Each QconCAT has the 
sequence for Glufibrinopeptide B (GluFib) located after the sacrificial peptide at the N-
terminus of the construct and a variant of this peptide, known as Fib, at the C-terminus before 
the HisTag. The value of GluFib and Fib is two-fold; firstly they can both be used as 
quantification peptides, a known amount of unlabelled versions of each can be spiked into a 
digest to quantify the labelled QconCAT and verify the quantification by virtue of each other. 
The peptides are common to each QconCAT so quantification is comparable between 
QconCATs. Secondly the presence of GluFib and Fib at the N and C-termini respectively allows 
for verification that the full length construct is present in the digest (Brownridge et al., 2011).  
An advantage of QconCATs is that the construct can be co-digested with the analyte protein, 
therefore minimising variation in digestion efficiency. Additionally QconCATs are not designed 
with any structural considerations and it is highly likely that the higher order structure of the 
analyte proteins will be more complex than the QconCAT, so if the analyte is denatured to 
allow complete digestion it is likely that the QconCAT should also be fully denatured.   
The QconCAT standard can be described as a multiplexed absolute quantification standard. 
The fact that standard peptides for several proteins can be produced and analysed 
simultaneously is both time and cost effective and is a major advantage of this method over 
other methods such as AQUA peptides as it facilitates easy multiplexing of quantification and 
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opens the possibility of much larger scale quantification projects. Once the QconCAT plasmid 
is created it can be used as many times as required without incurring great costs.  
Finally the design of the QconCAT in silico means that there is huge scope for what is included 
in the construct. For example, traditionally each peptide is included in the sequence once, 
resulting in equimolar 1:1 ratios of each, however it is possible to include peptides a number 
of times if different molar amounts are required in the analysis. This highlights the additional 
properties of the QconCAT which can be exploited to act as a standard in MS to assess 
instrument performance and condition. An example of this is the QCAL QconCAT (Eyers et al., 
2008); QCAL was designed to contain 22 different tryptic peptides, some included a number of 
times, and peptide masses selected to cover a wide range of m/z for MALDI-TOF and ESI-MS. 
The standard can be used for instrument calibration and to assess performance, it can also act 
as a common standard between laboratories to facilitate better exchange and standardisation 
of data.  
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2. Aims and Objectives 
QconCAT technology was designed to be used as a tool in proteomics for multiplexed 
quantification of several target proteins. In this thesis I demonstrate how the QconCAT 
methodology can be streamlined and the production process can be multiplexed, ultimately 
leading to a significantly shorter and simpler workflow. Figure 7 shows the overall workflow 
which is taken from the protocol originally published in 2006 (Pratt et al., 2006). The target 
boxes in green highlight the areas where the workflow can be developed in order to shorten 
and streamline the QconCAT protocol.  
My first objective was to remove unnecessary stages from the production process in order to 
shorten the overall production time frame. I investigated if it was possible to remove the re-
streaking of newly transformed QconCAT colonies and to eliminate the necessity for an initial 
trial induction of the QconCAT. The reproducibility of the QconCAT expression process was 
assessed to gauge whether the verification of the QconCAT construct could be delayed until 
after the stable isotope labelled protein was synthesised. 
I investigated alternative methods of E.coli cell lysis and protein purification to establish 
whether more rapid methods could be used. Additionally I sought to find methods which 
would allow for multiplexing of QconCAT purification, improving the efficiency of the 
production workflow.  
Finally I intended to demonstrate how QconCAT constructs can be used for more than 
quantification studies. With a study into 10 well characterised QconCAT proteins I considered 
the possible methods that could be used for quantification of the QconCAT standards and 
whether there are other potential applications for QconCATs as quality control standards.  
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Figure 7| Aims and objectives. Summary flow diagram of the original QconCAT production 
protocol and the number of days allocated to each stage. The diagram is annotated with 
targets for where time reductions and simplification of the protocol can be implemented.  
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3. Materials and Methods  
Reagents used are purchased from Sigma Aldrich, Dorset, UK including: Amino acids, both 
unlabelled and stable isotope labelled [13C6]Arginine and [
13C6]Lysine | Ampicillin salt | α-
cyano-4-hydroxycinnamic acid | Guanidine hydrochloride | Isopropyl β-D-1-
thiogalactopyranoside | Trypsin  
Other reagents were acquired as detailed below:  
Acrylamide (30% stock solution); Severn Biotech Ltd, Worcester, DY11 6TJ | Anti-mouse IgG; 
Cell Signaling Technology, Inc., Danvers, MA 01923 | Anti biotin IgG; Cell Signaling Technology, 
Inc., Danvers, MA 01923 | Anti his-tag monoclonal antibody; Novagen® from Merck KGaA, 
Darmstadt, Germany | Benzonase nuclease; Novagen® from Merck KGaA, Darmstadt, 
Germany | Biotinylated molecular marker; Cell Signaling Technology, Inc., Danvers, MA 01923 
| BugBuster; Novagen® from Merck KGaA, Darmstadt, Germany | Complete EDTA free 
protease inhibitor tablets; F. Hoffmann-La Roche Ltd, Basel, Switzerland | Coomassie Plus™ 
Protein Assay reagent; Fisher Scientific UK Ltd, Loughborough, Leicestershire, LE11 5RG | 
Dithiothreitol; Melford Laboratories Ltd, Chelsworth, Ipswich, Suffolk, IP7 7LE | Generon midi 
spin tube; Generon Ltd., Maidenhead, Berkshire, SL6 1AP | Luria-Bertani broth (MILLER); 
Merck KGaA, Darmstadt, Germany | Ni-MAC columns; Novagen® from Merck KGaA, 
Darmstadt, Germany | Ni-Superflow Resin; Generon Ltd., Maidenhead, Berkshire, SL6 1AP | 
Protino® Ni-TED resin and disposable columns; Macherey Nagel supplied by Fisher Scientific UK 
Ltd, Loughborough, Leicestershire, LE11 5RG | QconCAT coding sequence; designed by Craig 
Lawless, synthesised and supplied by Entelechon/PolyQuant GmbH, Industriestr. 1, 93077,  
Bad Abbach, Germany | RapiGestTM SF; Waters, Elstree, UK | SDS-PAGE Molecular Weight 
Standards, Broad Range; Bio-Rad Laboratories Ltd., Hemel Hempstead, Hertfordshire HP2 7DX 
| StrataClean™ Resin; Stratagene supplied by Agilent, Stockport, Cheshire SK8 3GR | 
SuperSignal West Pico Chemiluminescent Substrate; Thermo Scientific, 3747 N Meridian Rd, 
Rockford, IL USA 61101 | Yeast extract; Merck KGaA, Darmstadt, Germany 
NOTE: all of the solutions used in the methods 4.1-4.5 are sterilised before use either 
by autoclave or filter sterilisation 
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3.1 Transformation 
The QconCAT was designed as a gene which was cloned into a plasmid vector, for expression 
in the host BL21 (λDE3) strain. The plasmid vector used for QconCAT expression was pET21a 
which has a selectable ampicillin resistance marker and the inserted gene is placed under the 
control of a T7 promoter, meaning that expression of the gene is controlled using the T7 
expression system. 
For transformation (Mandel and Higa, 1970) the cells were made competent, therefore 
receptive to DNA, by treatment with calcium chloride, and heat shock was used to allow the 
DNA to enter the cell. The supplied 5μg of plasmid was solubilised in TE buffer (10mM Tris 
1mM EDTA) to a final DNA concentration of 1ng/ μl. 5μl (5ng) plasmid was combined with 
100μl aliquot of competent cells, and 42°C heat shock was used. The cells were pelleted (1677 
x g), resuspended in LB media and plated out onto ampicillin containing agar plates (50μg/ml) 
to allow for selected growth of only the transformed cells. Growth on the agar plates took 
place over 16hrs at 37°C. 
3.2 Glycerol stocks 
A single colony of transformed cells from the agar plate was used to inoculate 10ml of LB 
media (50μg/ml ampicillin), the broth was grown, at 37°C with 150rpm shaking to aerate the 
culture, to at least 0.6OD @600nm turbidity, before mixing 2:1 with 60% v/v sterile glycerol; 
glycerol stocks were stored at -80°C. 
3.3 Expression via LB IPTG 
A single transformed colony was used to inoculate 10ml of LB media, this was allowed to grow 
for 16 hours, 100μl of this culture was then used to inoculate a fresh flask of LB media. In the 
case of a trial induction (where expression of the QconCAT plasmid has not previously been 
verified) a small 10ml flask of LB was inoculated, in the case of a QconCAT already known to 
be expressed, 200ml of media was inoculated. The OD of the culture was measured at regular 
intervals until 0.6OD @600nm was reached; at this time IPTG was added to the culture at a 
final concentration of 1mM to induce expression of the QconCAT. Samples were taken 
throughout the culture time, both before and after induction, to measure the OD of the 
culture. These were subsequently centrifuged (1677 x g) and cell pellets resuspended in water 
to lyse the cells. Water was added in varying volumes calculated to make the concentration of 
the cell contents the same for all samples. Samples were then analysed by 1D SDS-PAGE to 
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assess QconCAT expression. The culture was harvested four/five hours later by centrifugation 
(1600 x g 15min). 
3.4 Expression via minimal media IPTG 
E.coli containing the QconCAT plasmid were grown in minimal media with amino acids 
[13C6]arginine and [
13C6]lysine, to elicit a stable isotope labelled standard. Typically 0.1mg/ml 
of each labelled amino acid was used in a 200ml culture to ensure complete labelling of the 
product. All other amino acids were unlabelled. The culture was grown under the same 
conditions as above, and induced with 1mM IPTG at 0.6OD @600nm. All samples taken for OD 
were retained for 1D SDS-PAGE analysis.  
3.5 Expression via autoinduction – unlabelled and stable isotope labelled cultures 
Solutions and media used as detailed in (Studier, 2005) both for unlabelled and stable isotope 
labelled cultures. Baffled flasks were used to increase aeration of the culture and improve 
culture growth. 1ml samples of the culture were taken at inoculation and immediately prior to 
harvest for analysis with 1D SDS-PAGE. 
3.6 Cell lysis using BugBuster 
One cell pellet from 50ml of culture was solubilised in 2ml BugBuster solution (solution made 
up with 25μl Benzonase Nuclease and 1 x Complete EDTA-free protease inhibitor tablet added 
to 25ml BugBuster). The pellet was left to solubilise for 20 minutes then insoluble material 
pelleted (12,200rpm). The supernatant was retained for 1D SDS-PAGE analysis. The insoluble 
material was then re-suspended in 2.5ml BugBuster solution and lysozyme added to a final 
concentration of 0.7mg/ml, the suspension was incubated at room temperature for five 
minutes before the addition of 15ml 1 in 10 dilute BugBuster solution. Inclusion bodies were 
pelleted (12,200 rpm) and the supernatant again removed and retained for 1D SDS-PAGE 
analysis.  
3.7 Cell lysis using sonication 
Cell pellet from 50ml of culture was re-suspended in 2.5ml 50mM phosphate buffer (pH8.0) 
plus protease inhibitors and benzonase nuclease (25ml buffer made up with 1 x complete 
EDTA-free protease inhibitor tablet and 25μl benzonase nuclease). The suspension was 
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sonicated at 30% amplitude in 10 second pulses every minute for 13 minutes. Inclusion bodies 
were pelleted (6000 x g 8min) and washed three times with 50mM ammonium bicarbonate.  
If sonicating a cell pellet prior to purification using Protino Ni-TED resin the pellet was 
resuspended in 5ml of LEW buffer (50mM NaH2PO4, 300mM NaCl, 1μl/ml benzonase nuclease, 
1 x complete EDTA-free protease inhibitor tablet per 10ml, pH8.0) Once the pellet was re-
suspended lysozyme was added to a final concentration of 1mg/ml and the suspension stirred 
on ice for 30min. After this time the suspension was sonicated as above and the inclusion 
bodies pelleted 10,000 x g 30min at 4°C. 
3.8 Purification with the Ni-MAC column method 
Ni-MAC nickel affinity columns are available in a kit containing columns and the four buffers. 
Buffers can also be made according to the standard recipe; bind, wash and elute buffers all 
contain 300mM sodium chloride, 50mM sodium phosphate, 6M guanidine hydrochloride and 
10mM, 20mM or 250mM imidazole respectively (pH8.0). Up to 20ml bind buffer was used to 
solubilise the inclusion bodies (prepared from a 50ml culture cell pellet) containing the 
QconCAT. After 30min incubation at room temperature with agitation to solubilise the 
QconCAT the solution was filtered through a 1.2μm syringe filter to remove insoluble material. 
The column was prepared with ultrapure water and equilibrated with bind buffer before 
loading the solubilised material onto the column (the starting material); the flow through from 
loading was collected and retained for 1D SDS-PAGE analysis. The column was washed with 
bind and wash buffers before eluting the QconCAT from the column with the elute buffer. 
Washes and elutes were collected in 1ml fractions.  
3.9 Preparation of purification fraction samples for SDS-PAGE analysis  
Samples of 20μl were taken from representative column fractions; for example the flow 
through, the first three 1ml fractions of the bind, the first three 1ml fractions of the wash and 
all of the 1ml fractions of the elute. A volume of 10μl StrataClean resin suspension was added 
to each sample along with 0.5ml water. Each sample was vortexed for one minute to allow the 
resin to bind the solubilised protein in the sample. The resin was washed with water to ensure 
the buffer components, especially guanidine hydrochloride, were removed. Reducing sample 
buffer was then added to the resin to allow the bound proteins to be released and the 
samples analysed on a 1D SDS-PAGE gel. The elution fraction(s) which contained the majority 
of the QconCAT protein were selected for dialysis. The fractions were dialysed against 50mM 
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ammonium bicarbonate solution over a period of ~20hrs at 4°C. The QconCAT solution was 
then removed from dialysis and stored at -20°C. 
3.10 Purification with the spin column method 
Buffers used for this method are similar to those used for the Ni-MAC column purification 
method, however for spin columns the buffers do not contain sodium chloride and the 
amounts of imidazole are slightly different; 10mM imidazole for bind buffer, 30mM imidazole 
for wash and 300mM imidazole for elute (all three buffers pH8.0). Unlike the Ni-MAC column 
purification, either one or two pellets of inclusion bodies (arising from one or two cell pellets, 
each from 50ml of culture) can be purified at one time. Each inclusion body pellet was re-
suspended in 1ml of bind buffer. The Ni-Superflow Resin was supplied as a slurry in ethanol, 
the ethanol was removed and the resin equilibrated in bind buffer before addition of the 1ml 
re-suspended inclusion bodies. A further 3ml or 6ml of bind buffer was added to the resin 
(depending on whether one or two inclusion body pellets are used) and the suspension was 
incubated with the resin for one hour at room temperature with agitation. The resin was then 
transferred to a midi spin column and the solution drawn through the resin with 200 x g 
centrifugation, the flow through was retained. In the same manner, the resin was washed 
using wash buffer and then the QconCAT eluted using elution buffer. The samples were 
treated with StrataClean resin, analysed using SDS-PAGE and dialysed as in method 4.9. 
3.11 Purification with Protino Ni-TED resin 
The Protino resin can be supplied in pre-packed columns, the method here used the free resin. 
A pellet of inclusion bodies (from a 50ml sonicated cell pellet) was resuspended in 10ml LEW 
buffer (recipe as above) to wash the inclusion bodies, the suspension was then centrifuged 
(10,000 x g 30min 4°C) and the resulting pellet was re-suspended in 2ml denaturing 
solubilisation buffer (50mM NaH2PO4, 300mM NaCl, 6M Gu.HCl pH8.0), the suspension was 
stirred on ice for 60 minutes. Remaining insoluble material was removed by centrifugation 
(10,000 x g 30min) and the supernatant retained. Protino resin was weighed out into the 
disposable column (1g) and equilibrated with denaturing solubilisation buffer before addition 
of the solubilised inclusion bodies; the column drained by gravity and the flow through was 
collected and retained. The column was washed with denaturing solubilisation buffer and then 
the QconCAT eluted using elution buffer (50mM NaH2PO4, 300mM NaCl, 6M Gu.HCl, 250mM 
imidazole pH 8.0). Method 4.9 was used to treat the fractions with StrataClean resin before 
analysis with 1D SDS-PAGE and dialysis.  
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3.12 Solubilisation in RapiGest as an alternative to purification  
The inclusion bodies pellet resulting from sonication in 50mM phosphate buffer was taken 
and washed three times with 50mM ammonium bicarbonate. 500μl of 4mg/ml RapiGest 
solution (0.4% w/v solution) was added to the final pellet, which was then re-suspended and 
DTT added to the suspension (1mM final concentration). The suspension was incubated at 
37°C with agitation for one hour to solubilise the QconCAT and then the insoluble material 
was pelleted (17136 x g). The supernatant was removed and diluted by the addition of 1.5ml 
25mM ammonium bicarbonate (25ml solution plus 1 x complete EDTA-free protease inhibitor 
tablet, 1.5ml aliquot used); the resulting QconCAT solution was stored at -20°C. 
3.13 Protein assay 
For some purified QconCAT samples a protein assay was performed. Bovine serum albumin 
(BSA) was used as a standard for the assay; concentrations of 10mg/ml, 20mg/ml, 30mg/ml, 
40mg/ml and 50mg/ml of the standard were used to construct a standard curve. Appropriate 
dilutions of the analyte protein solution were made so that the concentration fell in the range 
of the standard curve. Coomassie PlusTM protein assay reagent was mixed 2:1 with standards 
and analyte samples in duplicate. The absorbance at 620nm was measured using a Labsystems 
Multiscan Ascent colourimetric analyser and by comparing the absorbance of the analyte 
samples against the BSA standard curve the concentration of the analyte solution was 
calculated.  
3.14 1D SDS-PAGE gels  
12% reducing gels and reducing SDS-sample buffer were used. BioRad Broad Range Molecular 
Markers added to each gel. 
3.15 Western blotting  
Western blotting was used to assess the expression of a QconCAT if the QconCAT band was 
not obviously present on a 1D SDS-PAGE gel. The standard method for western blot transfer of 
a 1D SDS-PAGE gel was used (Towbin et al., 1979). To develop the western blot Anti-HisTag 
Monoclonal Antibody was used at a concentration of 0.05μg/ml, followed by Anti-mouse and 
Anti-Biotin antibodies (1 in 3000 dilution of supplied stock). In the dark room the 
nitrocellulose was then incubated for one minute in the mixed SuperSignal West Pico 
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Chemiluminescent Substrate solution before addition of x-ray film for up to five minutes.  The 
nitrocellulose was stained using Ponceau S.   
3.16 In-gel digests  
1mm3 plug was removed from a band of interest on a 1D gel. This plug was then destained in a 
2:1 solution of 25mM ammonium bicarbonate/acetonitrile. The plug was treated with DTT and 
Iodoacetamide (IAM) before dehydration in 100% acetonitrile. 10μl of trypsin (12.5ng/μl) was 
added to the dehydrated plug and incubated for 16hrs at 37°C. After this time the digest was 
stopped by the addition of 1% v/v formic acid (final concentration). 
3.17 In-solution digests 
An appropriate amount of protein was selected and diluted to bring the volume up to 160μl. 
The protein was then treated with 0.05%w/v final concentration of RapiGestTM at 80oC for 
10min, 3mM final concentration DTT 60oC for 10min and 9mM final concentration IAM room 
temperature for 30 minutes before addition of trypsin in a 50:1 ratio to the protein content of 
the digest. The final volume of the digest is 200μl. An overnight incubation was performed at 
37oC after which TFA was added to a final concentration of 0.5%(v/v), this acidification step 
hydrolyses the RapiGestTM and causes it to precipitate, it can then be removed from the 
solution by centrifugation leaving a clean digest ready for LC-MS analysis. During the course of 
its use the in-solution digest protocol was modified slightly and these changes are detailed in 
the results when used.  
3.18 Preparation for MALDI-TOF analysis of digests  
The sample, for analysis by MALDI-TOF, was mixed 1:1 with a 10mg/ml solution of α-cyano-4-
hydroxycinnamic acid in 50% v/v acetonitrile/0.1% v/v trifluoroacetic acid in HPLC grade water 
(matrix solution). Calibrants for the instrument were also mixed in the same 1:1 ratio with 
matrix. 2μl of the calibrant and of each sample were spotted onto a target.   
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4. Results and Discussion 
4.1 Production of QconCAT EB1 with the original protocol 
The EB1 QconCAT was synthesised for Dr Emøke Bendixen and Dr Stine L. Bislev (Bislev et al., 
2012). The construct consists of 40 peptides in a stoichiometric 1:1 ratio targeted to 20 
proteins which are indicators of the bovine host response to mastitis pathogens and 
inflammation. A peptide map shows the 44 tryptic peptides included in the construct (Figure 8 
(a)). There are two peptides targeted to each of the 20 proteins and the order of the peptides 
within the construct is optimised for maximum expression. At the N-terminus of the QconCAT 
there is a sacrificial peptide followed by a GluFib peptide which, as mentioned earlier, can be 
used for quantification. At the C-terminus there is another quantification and verification 
peptide, Fib, and finally the His-Tag sequence for purification. 
EB1 was made using a slightly altered version of the original QconCAT production protocol 
(Beynon et al., 2005; Pratt et al., 2006). The production process requires a time allocation of 
approximately 16 days to produce a product which is highly pure, well verified and suitably 
concentrated. The QconCAT plasmid was transformed into BL21 DE3 E.coli and the 
transformed cells selected for by antibiotic resistance to ampicillin; the antibiotic resistance 
gene in the QconCAT plasmid vector selectively allows the growth of only transformed cells on 
the antibiotic-containing agar plate. In this method the transformed colonies were re-streaked 
for a second overnight growth. Re-streaking of colonies ensures correct selection of a colony 
containing the plasmid and allows the plates to be re-used for up to two weeks after initial 
overnight growth (Brown, 1991). Using a colony from the re-streaked plate, a small LB broth 
was inoculated and after another overnight growth at 37°C the turbid culture was used to 
make glycerol stocks of the QconCAT-plasmid-containing cells. The turbid culture was also 
used to inoculate a further LB broth for trial-expression. After induction and a suitable growth 
time to allow for the QconCAT to be expressed to sufficient levels, a final culture sample was 
taken and the remaining culture discarded. The samples were analysed using 1D SDS-PAGE 
(Figure 8 (b)). 
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Post-induction with IPTG a new protein band at ~56kDa is seen on the SDS-PAGE gel that was 
not visible pre-induction (Figure 8 (b)).  This is the approximate mass for the QconCAT and the 
size of the band indicates a large amount of expressed product; over-expression is regularly 
seen with QconCATs. To verify the product was EB1, two 1mm3 spots were cut from the 
suspected QconCAT band and in-gel digestion performed. A sample of the digest was then 
mixed in a ratio of 1:1 with a solution of α-cyano-4-hydroxycinnamic acid matrix and analysed 
using MALDI-TOF MS (Figure 9).  
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The MALDI-TOF mass spectrum for the EB1 in-gel digest is complex and m/z values for all but 
three tryptic peptides are seen (Figure 9). It is expected that not all of the peptides will be 
seen in a MALDI-TOF spectrum, especially those at a lower m/z due to interference from 
matrix ion peaks. The high proportion of coverage of the QconCAT illustrated in the peptide 
map, coupled with the presence of peptides from the entire length of the sequence, confirm 
that the correct full length product has been made. The m/z for a missed cleavage between 
T20 and T21 has been identified; this suggests that digestion of that peptide bond was not 
complete. The sequence covering the missed cleavage site is: 
                T20                   T21 
 SETACHPLGKDQPTIDK 
        |----| 
       Missed cleave site 
      
Aspartic acid (D) is an acidic amino acid residue and the presence of this residue in the P1’ 
location (first amino acid after the basic lysine cleavage site) could affect the cleavage of the 
peptide bond leading to incomplete digestion (Brownridge et al., 2011).  
No other missed cleave m/z values are seen however missed cleaves could be too large to 
appear in the mass range analysed in this MALDI spectrum. As a digest to show the presence 
of the full length QconCAT the data is sufficient but complete digestion of the QconCAT 
cannot be shown.  
Once the correct QconCAT product was confirmed the stable isotope labelled QconCAT was 
made. An LB broth was again inoculated with a single colony. The turbid culture was used to 
inoculate a second starter culture of 10ml minimal media broth, this broth contains no amino 
acids; minimal media with [13C6]arg and [
13C6]lys amino acids is inoculated using this second 
starter culture. The amino acids contained in the minimal media are incorporated into any 
new protein the E.coli cells synthesise, this includes the QconCAT. Expression of the QconCAT 
was induced and the culture harvested after the suitable growth time. Expression of the 
QconCAT is indicated with an arrow to the QconCAT band (Figure 10 (a)).  
The culture was harvested into cell pellets resulting from 50ml of culture each. Because the 
culture produces more than is usually required in quantification studies only one cell pellet is 
processed at a time. For QconCAT EB1 the cells were lysed using BugBuster, which is a 
detergent reagent which acts to disrupt the cell membrane causing a release of the cell 
contents. Insoluble inclusion bodies (IBs) were recovered by centrifugation and SDS-PAGE was 
used to verify the presence of the QconCAT in the IBs. The IBs were then solubilised in a buffer 
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containing guanidine hydrochloride to denature the protein, and purified using the Ni-MAC 
purification protocol.  
 
Figure 10| EB1 heavy isotope labelling and NiMAC purification. (a). Expression of the 
QconCAT indicated by the black arrow. (b). Starting material of solubilised IBs, the flow 
through, binding (B) washes (W) and elutions (E) from the column all sampled and analysed 
using SDS-PAGE. QconCAT band in E1-E6 is the majority or sole band present.  
 
NiMAC Purification of the QconCAT elicits a highly pure product; this can be seen from the 
SDS-PAGE analysis (Figure 10 (b)). The QconCAT band is either the sole band in the elution 
fraction (E1, 3, 4, 5, 6) or the major band occupying the majority of the lane (E2). The elution 
buffer contains high levels of sodium chloride, guanidine hydrochloride and imidazole 
therefore dialysis is required to exchange the buffer to one more suitable for protein storage 
and compatible with MS analysis; the buffer usually used is 50mM ammonium bicarbonate. In 
the case of QconCATs that contain cysteines in their sequence there is a risk of di-sulphide 
linkages forming and causing the QconCAT to fold and precipitate. QconCAT EB1 contains 
seven cysteines which are shown in the QconCAT sequence below (orange). To prevent 
precipitation, DTT (a strong reducing agent) was added to the dialysis buffer to a final 
concentration of 1mM in order to reduce any disulphide bridges that might occur. A protein 
assay was performed on the dialysed QconCAT and the concentration calculated to be 
1.14μg/μl, equivalent to 20.1pmol/μl. 
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QconCAT EB1 amino acid sequence 
MGTKEGVNDN  EEGFFSARVT  TPGPHCDQTE  VIATLKTGNT  SENVNVNTAR  
|Q1|---------Q2------|------------Q3----------|---------Q4-----| 
LPPNVVEESA  RADLSGITKE  TIQGITDPLF  KGGQDITDFR  VQPQSLDLSH  
|------Q5-----|---Q6--|---------Q7-------|----Q8--|-------Q9---- 
NSLRVGYVSG  WGRNVHGINF  VTPVRNQLVE  VEKVTPPGPH  CGQTEVIATL  
----|-----Q10---|------Q11-----|-----Q12--|---------Q13--------- 
KNLENFLQFS  LRLGAAQVPA  QLLVAVLRAA  TAAAPRLGHY  DTLIQKEDHP  
|------Q14-----|---------Q15------|----Q16---|-----Q17----|-Q18- 
AGSVRLSISE  TYDLKSETAC  HPLGKDQPTI  DKIQHHTLLA  SPVRADQFAN  
-----|------Q19---|-----Q20----|---Q21---|-------Q22----|--Q23- 
EWGRDAGAWG  AEQRELPNFL  KIQVLVEPDH  FKVIESGPHC  ENSEIIVKNL  
----|----Q24-----|---Q25---|------Q26----|--------Q27--------|-- 
DLLEGAVTSA  SKQVFQEPCQ  YSPESQRDVE  LAEEVLSEKA  GGPQGSRIAD  
------Q28------|-------Q29-------|------Q30------|----Q31---|--- 
LITTPATNTD  LLEKVTTPGP  HCDQTEVIAS  LKNSAYAHVF  HDDDLRDSAP  
-------Q31-------|-----------Q32---------|-------Q34------|---- 
NTLSDLTTQA  LRNNQLVAGY  LQGPNTKDDN  NLCLHFNPRG  NDVAFHFNPR  
-----Q35-------|-------Q36-------|-------Q37-----|------Q38----| 
VVQVFVKVGH  FDTLNKYYGY  TGAFRGEADA  LNLDGGYIYT  AGKGVNDNEE  
--Q39--|-----Q40---|----Q41----|-------------Q42-------|---Q43-- 
GFFSARLAAA  LEHHHHHH 
------|------Q44------| 
 
The EB1 sequence follows the typical example set out in the introduction. Each peptide is 
indicated below the sequence. Q1 is the sacrificial peptide, Q2 the GluFib peptide (in purple) 
Q3-42 are the quantification peptides, Q43 is Fib (in purple) and Q44 is the hexahistidine tag 
(in blue) The location of the arginine and lysine residues, which denote the cleavage site for 
each peptide, are indicated with arginine in red and lysine in green. 
The final verification step for the QconCAT is to establish that it is fully labelled. An in-solution 
digest was performed on the purified QconCAT and analysed using MALDI-TOF MS (Figure 11).  
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In Figure 11 the +6Da mass shift for each QconCAT peptide is clearly visible compared against 
the spectrum for the light QconCAT. The intensities for the peptides do not exactly match 
between heavy and light forms however there is good correlation and some level of error is 
expected due to inherent errors in pipetting and variability in MALDI ionisation. The increased 
mass for each peptide across the entire mass range shows that the QconCAT has been 
successfully labelled and indicates full labelling. The QconCAT is therefore suitable for use in 
quantification studies.  
Section 1: modifying the QconCAT production protocol 
In order to produce QconCAT EB1 a number of set protocols were used, these successfully 
resulted in the required standard and were originally chosen for a number of reasons; cost 
effectiveness, ease of use, most effective results or equipment available. However depending 
on the number of QconCATs required and the time scale being worked to, the process could 
be considered lengthy and it does not easily lend itself to multiplexing. Many of the methods 
used can be changed, and during the course of my work with QconCATs I have made 
developments to the protocols in order to reduce time and cost of production.  
The QconCATs used during the rest of this study all pertain to the LOLA COPY project which is 
a BBSRC funded project aiming to quantify over 4000 proteins in the S.cerevisiae proteome, 
using QconCAT as the quantification strategy. QconCATs associated with this project are 
referred to as “COPYCATs” and are numbered in order of design date. The abbreviation “CC” is 
used for COPYCAT followed by a three digit number and the majority of further QconCATs will 
be referred to in this way.  
4.2 Reducing expression time  
The simplest step to consider removing from the protocol was re-streaking the transformed 
E.coli colonies before inoculation of an LB broth. In some cases it possible that a gene coding a 
recombinant protein can be excised from the pET 21a plasmid, the E.coli retains the plasmid 
so retains the additional properties, essentially the ampicillin resistance the plasmid confers, 
however the coding sequence for the protein is lost. If this occurs the E.coli colony will still 
grow on selective ampicillin agar plates, however expression of the recombinant protein from 
that colony is not possible. When a colony is re-streaked the morphology of the resulting 
colonies can be studied and a colony selected that has a typical morphology. In this way the 
probability of selecting a colony containing the full recombinant protein gene is increased. 
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However for QconCAT transformation the colony morphology from the first plating is regularly 
seen to be uniform which indicates universal uptake of the plasmid and retention of the 
QconCAT gene, therefore the re-streaking step was removed and inoculation with a freshly 
transformed colony seemed to have no detrimental effect on the culture. Removing this step 
reduces the production time by 1 day.  
The QconCAT is usually expressed in unlabelled form initially to check for expression and to 
verify that the correct product is being synthesised. After production of a large number of 
QconCATs it became clear that expression was consistently successful (Figure 12), for each of 
these QconCATs we observed expression of the correct protein construct. We saw no 
evidence for an incorrect, truncated or otherwise altered QconCAT being synthesised and this 
indicated that verification of the QconCAT product was not necessary for the continuation to 
stable isotope labelling. The production protocol was altered to eliminate the initial unlabelled 
expression and MALDI-TOF verification of the QconCAT; transformed colonies were instead 
taken on to immediate expression in minimal media with stable isotope labelled arginine and 
lysine. This “straight to heavy” approach removes at least six days from the production time. 
In ~85% of cases this approach is highly successful, however in ~15% of cases a QconCAT 
construct has failed to express. In these situations the heavy amino acids used in the culture 
are wasted, however the infrequency of this occurrence means that the benefits of removing 
a number of days from production time outweigh the negatives.  
Reduced expression time -6d and removed verification -6d 
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4.3 Alterations to the cell lysis protocol  
E.coli cells expressing EB1 QconCAT were lysed using BugBuster, a method which had been 
used a number of times in our lab successfully and which worked well for EB1. However with 
three QconCATs – CC001, CC002 and CC003 this method failed. CC001-003 expressed well in 
stable isotope labelled form (Figure 13 (a)), the cells were lysed using BugBuster, the inclusion 
body pellets solubilised and purified with nickel-affinity chromatography NiMAC cartridge. 
SDS-PAGE analysis of the fractions eluted from the Ni-MAC cartridge revealed a number of 
contaminant bands present in the elution lanes, in addition to the QconCAT band (Figure 13 
(b)). The SDS-PAGE gel for CC001 was selected and in-gel digestion was performed on the 
contaminant bands to establish the nature of the contaminants. Two potential sources were 
considered, either fragmentation of the QconCAT had produced these bands, or inefficient 
purification could have left E.coli proteins from the inclusion bodies in the eluate. The in-gel 
digests was analysed using MALDI-TOF MS and the results, although giving low coverage of 
the QconCAT, clearly indicated that the bands had resulted from QconCAT fragments rather 
than E.coli proteins (Figure 13 (c)).  
Next, the stage at which the QconCAT fragmented needed to be identified; the likely points 
could have been either immediately, as the QconCAT was expressed, during cell lysis, or 
during purification. An anti-Histag western blot was performed on the end-time-point samples 
from culture. This would show whether any fragments containing the HisTag were present 
during production and therefore whether the QconCAT was being fragmented immediately 
after synthesis. The western blot (Figure 14 (a)) shows a single his-tagged band for each time 
point sample; this shows a strong chance that the QconCAT was not fragmented in the intact 
cell. There is a possibility that the QconCAT had fragmented but that the fragments had lost 
their HisTag and so were not visible via western blot, but as the in-gel digests showed peptides 
which all came from the HisTag end of the QconCAT this is less likely. 
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Figure 13| Expression and purification of CC001-003. (a). SDS-PAGE, pre and post induction 
time point samples, whole cell lysate from E.coli culture, QconCAT band is seen in the post-
induction lane for each indicated by a black arrow.  (b). SDS-PAGE showing the starting 
material and eluted lanes 1 and 2 from purification of the expressed QconCAT, large number 
of bands present in the elution lanes in addition to the desired QconCAT band.  (c). Peptide 
maps shows the coverage of QconCAT CC001 from the in-gel digest of the highlighted bands.  
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Figure 14| Western blots tracking the fragmentation of CC001-003. (a). Whole cell lysate end 
time-point samples from unlabelled (light) and labelled (heavy) culture. QconCAT band visible, 
very small or no fragment bands seen.  (b). Sonicated inclusion bodies and soluble fraction, 
very small or no fragment bands seen.. (c). Soluble fraction and inclusion bodies blot with and 
without Benzonase Nuclease (+/-B). (d). NiMAC purification of CC001 inclusion bodies.  
Starting material contains the QconCAT band and additional bands, E1 and E2 contain 
QconCAT the elution as the sole band.  
 
It was observed that some of the bands in the elute lanes of the purification gels can also be 
seen in the starting material, for example with CC003 as indicated on the gel image by ret dots 
(Figure 13 (b)). This suggests that the QconCAT was already fragmented before it was loaded 
on to the column. This left two possibilities – either the QconCATs were fragmenting during 
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cell lysis or fragmenting during solubilisation of the inclusion bodies. To test if the 
fragmentation was occurring during cell lysis the method of lysis was changed to sonication. 
After sonication, the soluble fraction and the insoluble pelleted material were analysed using 
SDS-PAGE and western blot performed to look for HisTag bands. In the western blot (Figure 14 
(b)) some QconCAT is visible in the soluble fraction but the majority is in the insoluble pelleted 
material. Although there is clear overloading of QconCAT material there are no signs of 
fragmentation. It therefore looked likely that the source of the fragmentation was during 
BugBusting.  
There should not be any enzymes in the BugBuster solution, BugBuster is reported to disrupt 
cell membranes without damaging proteins (Novagen® product information) and it is a 
reagent which has been used successfully in our lab for quite some time therefore it was 
considered that the source of the fragmentation could be added during BugBusting. 
Benzonase nuclease is added during BugBusting and it was considered that this might be a 
source of proteases which could cause the fragmentation. This hypothesis was tested with 
COPYCAT CC002. A cell pellet was resuspended in phosphate buffer for sonication, the 
suspension was sonicated using the standard protocol and then two samples of this material 
were taken – to one sample buffer containing Benzonase nuclease was added, to the other 
just sample buffer was added. This was allowed to incubate for a short time before 
centrifuging to pellet the insoluble material. The supernatant was decanted and samples of 
the pellet and supernatant were analysed using western blot. Figure 14 (c) shows that the 
Benzonase nuclease appeared to have no fragmentation effects. 
The source of the fragmentation was still unknown, contaminants in that particular batch of 
BugBuster could have introduced proteases to the solution, however the alteration of lysis 
method solved the fragmentation problem. A comparison was drawn between sonication and 
BugBuster (Table 1). 
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Criteria BugBuster Sonication 
Time per sample 76m  
 2m resuspension 
 22m solubilisation 
 1m transfer 
 20m centrifugation 
 5m resuspension 
 5m incubation 
 1min vortex 
 20min centrifugation 
19m  
 1m resuspension 
 10m sonication 
 8m centrifugation 
Suitability for 
multiplexing 
Centrifugation, solubilisation and 
incubation steps can be 
multiplexed 
Centrifugation step can be 
multiplexed 
Time increase for 
multiple 
9m per sample  10m per sample 
Time for typical 8 
samples 
139m 89m 
Table 1| Comparison between BugBuster and sonication methods of cell lysis 
Sonication takes less time than BugBusting whether processing a single QconCAT or 8 
QconCATs in parallel. The change of cell lysis method reduced production time, making it 
possible for cell lysis and purification protocols to be easily completed in one day. The 
insoluble inclusion body material of each QconCAT CC001-003, resulting from sonication, was 
taken on to nickel affinity purification and the eluted QconCAT contained no fragment bands 
(Figure 12 (d)). Sonication was adopted as the standard cell lysis protocol.  
Reduced cell lysis time up to -½d 
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4.4 Alterations to the purification protocol  
SPIN COLUMN 
Purification of the QconCAT from the whole-cell lysate is achieved by nickel affinity 
chromatography using the HisTag, which is included in each construct. The standard 
purification method used for EB1 was Ni-MAC cartridge. The cartridges come ready prepared, 
containing nickel immobilised on resin, 1ml of which is packed into a column. Solubilised 
QconCAT is loaded onto the column at a rate of about 0.5ml/min, the column is washed and 
then the QconCAT eluted off. This method produces a pure product but is time consuming and 
difficult to multiplex without the use of a peristaltic pump or simultaneous delivery method. 
For this reason other methods were considered. The first of these was spin column 
purification using resin from Generon. This method uses the same principles as Ni-MAC 
purification, where immobilised Ni2+ ions bind to HisTagged QconCAT and the pure QconCAT is 
eluted after washing of the resin. In the case of spin columns the resin is packed into a column 
within a centrifuge tube and rather than pumping the liquid through the column at a set flow 
rate, the column of resin is centrifuged to bring the liquid through the resin. This method of 
flow means that a number of columns can have QconCAT applied at any one time and all 
centrifuged simultaneously, thereby multiplexing the purification process.  
In order to refine the method, I varied and monitored the volume of resin used, the amount of 
IBs used and the volume of binding buffer in which the IBs were added to the resin. The 
results of varying these three factors are shown in Figure 15. For the first purification trial (gel 
(a)) one IB pellet of CC001 (arising from the sonication of a cell pellet from 50ml of culture, 
which should contain ~7.5 x 1010 cells) was solubilised in 4ml of bind buffer and incubated with 
1ml of resin. The reported binding capacity of the resin is up to 15mg/ml resin depending of 
the protein. The protein assay of the starting material (shown in Table 2 in Figure 15) gave the 
total protein content of the 4ml solubilised IBs to be 3.4mg, it would be expected that the IBs 
do not contain just the QconCAT protein, therefore the actual amount of QconCAT would be 
less than 3.4mg, however as the majority protein in the solution (see starting material (SM) 
band to see the overwhelming presence of the QconCAT) 3.4mg is given as an estimate. As 
this amount of protein is less than the reported binding capacity of the resin it was presumed 
that 1ml resin should be more than adequate to bind all of the QconCAT. The results showed 
that some QconCAT had not bound to the column and had come through in the flow through 
but it seemed from the gel that the majority of the QconCAT was present in fractions E1 and 
E2. However, the values from the protein assay, in the table, do not reflect the gel; the assay 
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indicates 30% of the QconCAT was recovered, therefore a large amount either did not bind to 
the column and was washed off, or still remained on the resin. A sample of the resin was 
analysed using SDS-PAGE by washing the resin with water before adding reducing sample 
buffer and loading approximately 10μl of beads onto the gel; this analysis did not reveal any 
protein bands removed from the beads (results not shown). It was therefore likely that a 
significant proportion of the QconCAT protein did not bind to the resin in the first instance 
and was washed off the column in the flow through.  
We have found that, although the amount of QconCAT produced varies between constructs, 
on average a 200ml labelled culture (~3 x 1011 cells) provides a minimum of 1.5mg protein, 
which is ~25nmol (based on average molecular weight of 60,000Da). Each culture therefore 
provides enough material for ~1000 quantification studies if 20-30pmol of QconCAT is used in 
each study. The loss of QconCAT during the purification method is therefore not necessarily a 
problem, a compromise can be drawn to use a method which is lossy but rapidly generates 
enough useable material for the required studies.  
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Figure 15| SDS-PAGE of fractions from purifications using spin columns. (a). Purification of 
QconCAT CC001, 1 IB pellet added to 1ml resin in a 4ml volume. (b). Purification of QconCAT 
CC002, 1 IB pellet added to 0.5ml resin in a 4ml volume. (c). Purification of QconCAT CC002 1 
IB pellet added to 0.25ml resin in a 0.5ml volume Table 2| Protein assay results Comparing 
the recovery from the different conditions of purification. The largest recovery comes from 
purification A. (d). Purification of QconCAT CC003, 2 IB pellets added to 2ml resin in a 5ml 
volume. (e). Purification of QconCAT CC001, 2 IB pellets added to 2ml resin in a 5ml volume.  
 
It was possible that the ratio between the starting material volume and the amount of resin 
was not optimal for complete binding; two more purification conditions were screened, one 
with half the amount of resin with the same volume of QconCAT (Figure 15 gel (b)) and the 
other with a quarter the amount of resin in a quarter volume of QconCAT (Figure 15 gel (c)). In 
gel (b) there is a large amount of QconCAT seen in the flow through lane, the protein assay 
also reports that much less QconCAT is recovered – 12%. In (c) again a large amount of 
QconCAT is seen in the flow through. Additionally there is also QconCAT seen in the washes, 
and a number of additional bands in the elute lanes. Although the protein assay shows the 
FT W1 W2 E1 E2
(d) – CC003
Purification Starting material total amount Dialysed material total amount Percentage of QconCAT material recovered
A 56.0nmol/3488ug 17.08nmol/1067ug 30.5%
B 58.2nmol/3547ug 6.84nmol/416.6ug 11.75%
C 58.9nmol/3589ug 10.3nmol/626.6ug 17.5%
(a) – CC001
SM W1FT W2 E1 E2 SM FT W1 W2 E1 E2
(b) – CC002
SM FT W1 W2 E1 E2W3
(c)C – CC002
(e) – CC001
SM FT W1 W2 E1 E2
Table 2| Protein assay results
Key: 
SM = starting material
FT = flow through
W1,2 = wash fractions
E1,2 = elute fractions
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amount of recovered QconCAT is not as low as in (b) (17.5% recovered) it is still lower than the 
recovery for (a). Lowering the volume of resin used was therefore concluded to be ineffective.  
The next investigation was based on the hypothesis that the concentration of the QconCAT in 
the starting material was not optimal for complete binding. For (d) and (e) two inclusion body 
pellets were used, with 2ml of resin in a volume of 5ml. For CC003, Gel (d), 14.5nmol of 
material was recovered. When the conditions were repeated for CC001 there was good 
recovery, however the elution contained a number of additional proteins shown by bands 
seen in the elute lanes on the gel. Moreover, when 1mM DTT was added to the buffer during 
dialysis of CC001 the QconCAT solution turned gradually brown over a period of ~2hr 
(previous QconCAT solutions had been uncoloured). This occurred for a number of different 
QconCATs under the same purification conditions, the image below(Figure 16) shows an 
example of the QconCAT solution after DTT addition:  
 
Figure 16 | Brown QconCAT solution post-dialysis in 50mM ammonium bicarbonate with 
1mM DTT 
It is likely that the brown solution was an indication that the nickel in the affinity purification 
was leaching off the column. Other purification methods had been suggested and the spin 
column purification method was abandoned in favour of alternative methods where this 
discolouration was not observed.  
It was observed that the intensity of the protein bands on the purification gels do not 
necessarily reflect the quantities stated in the protein assay; this is likely due to the use of 
StrataClean resin. The fractions eluted from the affinity purification column contain imidazole 
and guanidine hydrochloride, which need to be removed before running a sample of the 
fraction on a gel. In order to do this StrataClean resin is used to bind the protein in the sample 
and the resin is then washed to remove unwanted chemicals before loading the resin onto a 
gel. Variations in the binding capacity of the resin, the amount of sample loaded onto the 
resin in a set volume, the ability of the sample buffer to remove the protein from the resin and 
the number of beads that are able to be loaded onto the gel all affect the final amount of 
protein seen and could account for the disparity between the two assays.  
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FLOW THROUGH STUDY 
During the purification process it was noted than QconCAT protein is invariably seen in 
analyses of the buffer which flows off the column during loading of the QconCAT (known as 
the “flow through”). The binding capacity of NiMAC column resin was reported to be variable 
depending on the protein being bound, with an upper limit of 30mg/ml. The presence of 
QconCAT in the flow through could be attributed to:  
1. The resin being fully saturated therefore unable to bind all of the QconCAT  
2. The resin not being incubated with the QconCAT for a long enough period of time  
3. The resin not being incubated with the QconCAT in sufficient volume of buffer to 
allow complete mixing 
4. The QconCAT may have lost the HisTag and therefore be unable to bind to the resin  
To investigate which of these was correct a small study was undertaken. QconCAT CC050 was 
selected at random for this study. Three cell pellets of CC050, each produced from 50ml of 
culture, were used. The pellets were resuspended and sonicated individually. After sonication 
the three suspensions were combined and mixed well before removal of 3 x 2ml volumes (the 
rest of the solution was retained but not used), the three 2ml volumes were therefore 
identical. They were centrifuged for 8min 6000 x g to pellet the inclusion bodies in each; the 
pellets were washed once in 25mM AmBic and were then solubilised and purified using 
NiMAC cartridge, each pellet taken through a different method.  
Method 1: Standard purification; the QconCAT was loaded onto the column followed by bind 
buffer, wash buffer and finally elute buffer passed through the column, the QconCAT was 
eluted and retained. Samples of each fraction were analysed by SDS-PAGE.  
Method 2: Re-applying the flow through; the QconCAT was applied to the column and the 
flow through collected as usual (FT 1 sample). The flow through was then immediately passed 
through the column a second time and the flow through was collected again (FT2 sample) – 
flow through 2 was collected in small fractions with a sample of each fraction removed for 
SDS-PAGE analysis, this was to allow for monitoring of the elution profile of the QconCAT if 
any remained in FT2. Bind, wash and elute buffers were passed through the column, the 
QconCAT was eluted and samples analysed by SDS-PAGE.  
Method 3: Two sequential purifications; the specifications for the NiMAC cartridges 
recommend only purifying one protein per column but that the column is useable for multiple 
rounds of purification of that protein, the column can be washed and stored in buffer at 4˚C to 
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be used up to 10 times. For this method the QconCAT was loaded onto the column, flow 
through 1 was collected and the purification proceeds according to the standard protocol, the 
QconCAT was eluted off the column, the column was then washed in storage buffer, water 
and then bind buffer to re-equilibrate the column. Flow through 1 from the first round of 
purification was then re-applied to the column; the resin had been washed so should be able 
to bind any QconCAT present in the flow through 1. Samples were again collected in fractions 
from flow through 2, the purification was then completed according to the usual protocol and 
samples analysed by SDS-PAGE.  
The results of the study are seen in Figure 17. For gel (c) the QconCAT band can be seen in the 
flow through as expected. In gel (d), where the flow through was immediately re-applied to 
the column, there is a slight reduction of QconCAT material between FT1 and FT2 but not 
significant, there is still a QconCAT band in FT2. In gel (e) QconCAT material can be seen in the 
FT1. This material was reapplied to the column after elution and washing. FT2 (gel (f)) still 
shows some material is not binding to the column however QconCAT bands can be seen in E1, 
E2,E3 and E4 lanes, showing that QconCAT has bound to the column from FT1. The protein 
assay results for the purifications do not seem to reflect the gels. In the 3ml recovered after 
each purification 1-3, from method 1 0.39mg was recovered, for method 2 0.082mg was 
recovered and for method 3 0.36mg was recovered in the first round and 0.18mg in the 
second round giving a total of 0.53mg. There is an obvious anomalous result for purification 
with method 2. The amount of material recovered is much lower than the other purifications 
with no obvious reason as to why this would be; the QconCAT is visible in the elution lanes 
and the eluted fractions were all handled and dialysed in the same way for each purification; 
this result cannot be used in concluding the results of the study. The results of purification 
method 3 show that the QconCAT which comes through in the flow through can be re-bound 
to the column and the total amount of protein recovered is greater than with a single 
purification round. Tt can therefore be concluded that the QconCAT has not lost the HisTag, 
and that this cannot be the reason why the full amount of QconCAT does not bind to the 
column. It can be speculated that the likely cause for the QconCAT in the flow through is that 
the resin is saturated under the current conditions. However, the sampling through the flow 
though 2 for methods 2 and 3 (gels (a) and (b)) showed that the QconCAT elutes into the flow 
though continuously rather than saturating the column and then running off, therefore it 
could be speculated that the binding conditions are also affecting the amount of QconCAT 
which binds the column. A sure solution to acquire more material, as shown by this study, is to 
use two rounds of purification.  
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RAPIGEST SOLUBILISATION 
The results from the flow-through study suggest that further optimisation of the purification 
method would lead to more complete recovery of the QconCAT. Purification is already a 
relatively time-consuming process and in a high-throughput workflow could be a significant 
rate limiting factor. Whilst the amount of QconCAT recovered is usually adequate for the 
quantification studies we perform, depending on the study and the type of analysis more 
QconCAT may be required and a “lossy” method could be costly. Further optimisation of 
purification would be time-consuming and possibly add further time to the protocol. For this 
reason other options were considered. It was observed that in the starting material for a 
purification the overwhelming majority protein is QconCAT. The starting material is simply 
solubilised IBs, therefore QconCAT is the majority protein in the IBs. Given this fact a possible 
alternative to purification was therefore to try using the un-purified IBs; with the QconCAT 
being the majority protein the other proteins present would be diluted to a level where they 
would become insignificant during use. Additionally the presence of the two internal 
quantification peptides means that pure protein is not required for the accurate quantification 
of the standard.  
For the first trial the IBs of CC001 were washed in 50mM AmBic three times before solubilising 
in 6M guanidine hydrochloride and 1mM DTT; this is the same concentration of guanidine 
hydrochloride as used in the Bind Buffer for purification. Solubilisation took place over five 
hours with the solution agitated on an end-over-end mixer, before centrifuging to pellet the 
insoluble material, dialysing it against 50mM AmBic and analysing the soluble fraction via SDS-
PAGE. A comparison was drawn between a sample of Ni-MAC purified CC001 and the washed 
CC001 (Figure 18 (a)). There are contaminant bands present in the lane for washed CC001, 
however the QconCAT protein is the majority band. Whilst each contaminant band 
individually is significantly weaker than the CC001 band it was considered the other methods 
of solubilisation might increase the concentration of CC001 in solution and so increase the 
percentage relative to other contaminant proteins.  
Guanidine hydrochloride was used for the initial trial to solubilise the QconCAT as it is used in 
the purification buffers to denature the QconCAT protein to solubilise it. Other solutions to 
solubilise the QconCAT were considered, one of which was RapiGest solution. RapiGest is a 
standard component of our digest protocols. It is a detergent which is used to disrupt the 
structure of the proteins in the digest, allowing trypsin access to the entire length of the 
protein to ensure complete digestion. As it disrupts the structure of proteins it was considered 
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that RapiGest could help to solubilise the QconCAT, additionally as it is part of our standard 
digest protocol the RapiGest would not need to be dialysed out of the solution prior to use of 
the QconCAT. An IB pellet of CC001 was sonicated and for ease of use, to give better washing 
and for further investigation, the 2.5ml of sonicated material was split between two 2ml tubes 
before centrifuging. The soluble fraction was removed (SF1) and a sample retained. The two IB 
pellets were then washed three times in 50mM AmBic, samples taken of each soluble fraction 
(SF2-4). Finally the two pellets were solubilised in RapiGest – one pellet was solubilised in 
250μl of 0.4% RapiGest solution and the other solubilised in 250μl of weaker 0.1% solution. 
Each pellet was left for 30 minutes to solubilise, the insoluble material centrifuged and the 
soluble fraction removed and retained. The gel image (Figure 18 (b)) shows the more 
concentrated RapiGest method results in a greater amount of QconCAT in solution and this 
was decided as the best method for solubilisation. The final gel (Figure 18 (c)) shows that if the 
0.4% solubilised QconCAT is diluted to a level which is normally seen for an average protein on 
a gel, no other protein bands are visible.  
For storage the solubilised material was diluted by the addition of 750μl of 25mM AmBic 
containing protease inhibitors before aliquotting and storage at -20˚C. On thawing, some 
aliquots of different QconCATs developed a precipitate. To prevent this from occurring in 
further solubilisations 1mM DTT was added to the RapiGest during solubilisation. Finally, 
during the digest protocol the digest is heated to 80˚C after addition of the RapiGest, this level 
of heat is not suitable for the QconCAT solubilisation but gentle warming to 37˚C for 1 hour 
was added to the protocol to increase the efficiency of the RapiGest solubilisation.  
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Figure 18| RapiGest solubilisation development. (a). Comparison of washed and purified 
CC001 material. (b). Different concentrations of RapiGest solution used to solubilise IB 
material, with 0.4% being most effective. (c). Diluted RapiGest solubilised CC001 shows a 
single QconCAT band.  
 
To verify that the QconCAT was the majority protein in the solubilised material and also that 
any additional proteins present in the QconCAT solution would not interfere with using the 
QconCAT, two further investigations were performed. First, dilutions of the solubilised 
QconCAT were analysed by SDS-PAGE and densitometry performed on the protein bands to 
analyse the percentage content of each major band in the soluble fraction. The results show 
that the solubilised QconCAT occupies 69-80% of the lane on the gel, with an average of ~75%.  
In Figure 18, gel (c) shows that increasing dilutions of the QconCAT solution eventually lead to 
a lane where only the CC001 band is visible (1 in 100 dilution). This shows that, whilst the 
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contamination from E.coli proteins cannot be removed, the solution can be diluted to an 
extent where the contaminants are not significant. In a typical digest the QconCAT is diluted 
~1 in 35; at a 1 in 20 dilution contaminant bands are still visible and although the QconCAT is 
diluted more than this for analysis there was therefore a concern that, even though the 
QconCAT was the majority protein in the solubilised material, the lack of purification would 
mean the introduction of other proteins into a digest and could affect the MS data and 
quantification. To check this, one aliquot of purified CC001 and one aliquot of non-purified 
RapiGest solubilised CC001 were digested separately. RapiGest is part of our usual digest 
protocol so was used with the purified CC001 for digestion, the key difference between the 
two CC001 samples is that one is purified and one is solubilised. The digests were analysed 
using LC-MS/MS and the results were compared against an E.coli protein database, the 
protein hits for each can be seen in the tables below.  
Accession Description mW (Da) Coverage (%) 
B1X9B6 Small heat shock protein ibpB  16083 27.46 
B1X9B7 Small heat shock protein ibpA  15764 18.97 
B1XEK3 Methylmalonyl CoA decarboxylase biotin independent  29153 4.59 
B1XBY2 Elongation factor Tu  43286 19.54 
B1X6E8 30S ribosomal protein S4  23454 17.47 
Table 3| RapiGest solubilised CC001, protein hits from the E.coli database 
Accession Description mW (Da) Coverage (%) 
B1XEK3 Methylmalonyl CoA decarboxylase biotin independent  29153 4.59 
B1X6I9 Elongation factor Tu  43256 15.98 
Table 4| Purified CC001, protein hits from the E.coli database 
The protein hits found, as expected, are some of the most abundant proteins in E.coli 
(Ishihama et al., 2008). The fact that two E.coli proteins were found in the purified QconCAT 
digests (Table 4) indicates that whichever method is used for the preparation of IBs, 
contaminant proteins cannot be completely removed from the QconCAT solution. The small 
increase of protein hits from two, in the purified, to five in the RapiGest solubilised 
preparation (Table 3) suggest that there is not a great level of purity lost in simply solubilising 
the QconCAT.  
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RapiGest solubilisation is only effective if the QconCAT is over-expressed to an extent that the 
ratio between QconCAT protein and contaminant proteins is high. The majority of QconCATs 
are over-expressed, however some are not expressed to the levels which are required and 
these still need to be purified. The QconCAT is not quantified until after solubilisation or 
purification, so protein content cannot be easily assessed, and therefore cannot be used as a 
deciding factor for how the QconCAT is prepared for use. As a deciding rule the E.coli protein 
band indicated by the arrow (Figure 19), an E.coli protein that is present in every expression 
culture whole cell lysate, is compared to the QconCAT band (protein identified by Dr Amy 
Claydon as outer membrane protein F, PhD thesis “Approaches to understanding the dynamic 
proteome”, September 2009). If the QconCAT band is as strong as, or stronger, than the E.coli 
protein band then the QconCAT is RapiGest solubilised; if the band is weaker than the E.coli 
band then the QconCAT is purified. 
  
Figure 19 | QconCAT selection for purification or RapiGest solubilisation . Whole cell lysate 
samples from expression cultures, the red dot indicates the expression band. QconCATs CC058 
and CC100 were RapiGest solubilised, CC101 and CC102 were purified.  
Reduced purification time -1d and enabled multiplexing therefore reducing purification time 
further depending on the number of QconCATs being processed 
There is an optimal QconCAT production workflow for the majority of “well behaved” 
QconCATs, easily multiplexed and high throughput which involves the use of all of the 
protocol improvements I have set out so far in this thesis. There are also troubleshooting and 
alternative methods for QconCATs which show atypical behaviour. The overall flow diagram 
for the optimised methods can be seen in Figure 20. 
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4.5 The optimised method and troubleshooting 
In Figure 20, the ideal optimised method is shown. The green top line represents the ideal 
workflow where the QconCAT expresses well and the inclusion bodies can be solubilised in a 
RapiGest solution for use. This happens in ~70% of cases. In ~10% of cases the QconCAT 
expresses to a lower level and needs to be purified, occasionally with western blot verification 
prior to purification to verify expression has occurred, this is shown in yellow. In ~20% of cases 
the QconCAT fails to express and needs to be redesigned, this is shown in red (data from COPY 
project COPYCATs).  
So in the majority of cases the optimised, high throughput method works well. However there 
have been QconCATs where the protein did not express well, or did not express at all, and 
occasionally although the QconCAT expresses, it is more difficult to solubilise. In these cases 
troubleshooting protocols need to be used. The mostly commonly used tool when 
troubleshooting QconCATs, specifically very low expression of the QconCAT protein, is 
western blotting. Each QconCAT is designed with a HisTag at the C- terminus for purification 
and this tag can also be used to identify the presence of the QconCAT with a western blot; an 
anti-HisTag antibody is used along with a chemiluminescent substrate, x-ray film is used to 
develop the blot and the presence of the QconCAT is indicated by a black band.  
Less common is where a QconCAT does not express well in a certain type of media. QconCAT 
Ribo4 was one of four QconCATs, designed for a study into yeast ribosomal proteins, which I 
expressed. Ribo4 showed low levels of expression in LB media (Figure 21 (a)), even with 
elevated levels of IPTG.  To try to improve expression two other culture conditions were tried; 
culture in autoinducing media and IPTG induction in minimal media with light amino acids 
(Figure 21 (b)). The SDS-PAGE analysis of time points from these cultures show that in the 
minimal media and autoinduction media Ribo4 seems to express to improved levels. As 
minimal media is used for expression of the stable isotope labelled protein a heavy culture 
was then attempted. The heavy Ribo4 protein was expressed to adequate levels and was 
purified to yield a clean product (Figure 21 (c)). 
Some QconCATs do fail to express entirely. The exact cause for this is unknown. A possibility is 
that the QconCAT produced could be toxic to the E.coli cells in some way, however this might 
be indicated by a lack of culture growth and this is not usually observed; it may be more likely 
that the QconCAT is not being synthesised. The usual solution in these cases is to change the 
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order of the peptides in the QconCAT gene and order a new construct, re-expression is then 
attempted. 
 
 
 
 
Figure 21 | Ribo4 QconCAT expression in different media. (a). Expression in LB with 2mM 
IPTG induction. Time point samples T0-T7 assessed. Low level expression seen faintly band in 
T4 and T5. (b). Minimal media and autoinducing media  with improved QconCAT expression. 
(c). After stable isotope labelled culture Ribo4 is successfully purified.  
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Section 2: QconCAT protein as a quality control standard 
The design of a QconCAT is inevitably selective. The peptides included in the construct are 
carefully chosen using the criteria previously discussed; one of these criteria is how well the 
peptide will behave during the mass spectral analysis. This means that each QconCAT that is 
produced is not only a quantification standard, it is also a protein consisting entirely of 
peptides designed to behave predictably in a mass spectrum. It was therefore considered that 
these proteins could be used for more than protein quantification; they could also be used to 
assess instrument performance under a number of criteria including quantitative 
performance. This idea is not new, as previously discussed Eyers et al. (Eyers et al., 2008) 
designed their own QconCAT to use as a MS standard, however the approach taken here was 
different to QCAL in that the focus was to explore a different aspect of instrument 
performance - the ability of the instrument to detect and quantify peptides over a large 
dynamic range in a more complex sample than a single protein. Sigma-Aldrich® have also 
made a Universal Proteomics Standard (UPS1) which is an equimolar mix of 48 human 
proteins and a Proteomics Dynamic Range Standard (UPS2) which is a dynamic range mix of 
the same 48 human proteins ranging from 500amol to 50pmol in concentration; both 
formulations are designed to assess chromatographic and instrument performance. The 
purpose of this study was to assess whether QconCATs could be used in a similar way to the 
UPS1 and 2 standards with the addition of assessing quantitative performance and the benefit 
of the flexibility that comes from a “designer” set of proteins where the peptides are as well 
characterised as the protein itself. 
Ten COPYCATs were selected to cover a dynamic range of 0.5fmol on column up to 0.5pmol 
on column with 8 concentration points between. Each of these was known to express well, no 
other selection criteria were used.  The COPYCATs selected were 001, 002, 042, 043, 045, 052, 
053, 058, 059 and 060. For this study each COPYCAT was expressed in unlabelled form; as the 
COPYCATs were not going to be used for quantification it was not necessary to distinguish 
them from an analyte. The time point samples for each COPYCAT culture before (-) and after 
(+) addition of IPTG show variable levels of expression for the 10, the expression bands, 
indicated with a green dot, are visible for each to indicate successful expression (Figure 22 
(a)). A cell pellet from each COPYCAT culture was then purified using NiMAC cartridge and the 
purified material was analysed in a 1 in 2 dilution using SDS-PAGE to verify no contaminant 
bands could be seen (Figure 22 (b)).  
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Figure 22| Expression and purification of 10 unlabelled COPYCATs. (a). SDS-PAGE of pre (-) 
and post (+) induction samples for COPYCAT expression in LB media. (b). The diluted purified 
material for each COPYCAT with a clean band for each, arrows indicate which band pertains to 
which COPYCAT.  
 
In order to use the COPYCATs effectively they first needed to be accurately quantified. The 
first study using these 10 QconCATs was to assess the variability in quantification of the 
QconCATs using various methods.  
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4.6 Methods for quantification of the QconCAT standards 
The accuracy of quantification using a standard is largely dependent on how well the standard 
itself is quantified. It is therefore extremely important in quantitative proteomics to select the 
most appropriate method for quantification of the standard and to be sure that this 
quantification is reliable. With respect to the study of 10 COPYCATs, to get the proteins into a 
dynamic range each COPYCAT needs to be accurately quantified. There are a number of 
different ways to quantify a standard and I investigated the use of a few of these.  
The methods used for quantification: 
Method Merits Demerits 
Densitometry  Whole protein quantification 
 Visual check for contaminants 
possible 
 Reliant on staining of a different 
protein to act as a standard, 
variation in dye binding 
behaviour could bias results  
Protein assay  Whole protein quantification   Reliant on staining of a different 
protein to act as a standard, 
variation in dye binding 
behaviour could bias results 
Quantification 
via the GluFib 
peptide on the 
QconCAT, using 
MALDI-TOF-MS 
 
 Standard and analyte target 
peptide are almost identical, 
increasing accuracy of the 
quantification 
 Sample and analyte are 
combined early on in the 
workflow, decreasing the 
possibility of error introduced 
during sample preparation 
 Digestion required which may 
introduce error if incomplete 
 Comparison of a single peptide 
to a standard, needs to be a 
quantotypic peptide  
 MALDI-bias towards Arg 
containing peptides  
 Single QconCAT protein 
quantified in each analysis 
Quantification 
via the GluFib 
peptide, using 
ESI-QTOF-MS 
 
 Standard and analyte target 
peptide are almost identical, 
increasing accuracy of the 
quantification 
 Sample and analyte are 
combined early on in the 
workflow, decreasing the 
possibility of error introduced 
during sample preparation 
 Digestion required which may 
introduce error if incomplete 
 Comparison of a single peptide 
to a standard, needs to be a 
quantotypic peptide 
 Single QconCAT protein 
quantified in each analysis 
Label-free 
quantification, 
using ESI-QTOF-
MS 
 
 Rapid quantification of 
multiple standards 
simultaneously from MS data 
processing  
 Multiple proteins can be 
quantified in a single analysis  
 Digestion required which may 
introduce error if incomplete 
 Comparison of top3 peptides 
from the analyte to the top3 
standard peptides from an 
entirely different protein 
Table 5| Merits and demerits of five different quantification methods for the QconCAT 
standard 
Results and Discussion 
  80 
These methods for quantification differ in the target; for the protein assay and densitometry it 
is the entire protein which is being used in the assay. In the case of quantification using GluFib 
it is a single target peptide within the digested COPYCAT, and for label-free a selected number 
of “top” intensity peptides are used, in this case the top three. In these methods, except for 
label-free, the COPYCAT is quantified by comparison with a standard which is present in a 
known amount.  
DENSITOMETRY 
For the densitometry, bovine serum albumin (BSA) was used as the standard for 
quantification. Several SDS-PAGE gels were run to include a range of dilutions of BSA in order 
to obtain the best quantification for each COPYCAT.  A BSA standard graph was drawn for each 
gel and the equation for the best-fit line was only applied to COPYCATs from the same gel. The 
densitometry gels can be seen in Figure 23 along with their corresponding BSA-standard plots. 
The value for the absorbance of each band is given as a “volume”, for the BSA standard this 
volume can be equated back to the amount of protein loaded on to that lane of the gel by 
plotting the corresponding values in a graph; this results in the BSA standard plots seen with 
the line of best-fit being used to calculate the quantification of the analyte COPYCATs. The 
amount of COPYCAT, in ng, on the gel was calculated. For CC001 a number of different 
dilutions were run to assess the consistency of the readings; an average ng on gel value for 
CC001 was therefore calculated.  It should be noted that for CC002 the band was stronger 
than the highest amount of BSA for that gel, however the value was still included as the line-of 
best fit gave a good Pearson's r value of 0.96 and an adjusted R2 value of 0.89 (values from 
OriginLab programme 8.5) and it was decided that the error introduced by extrapolating from 
the line would not be significant. The results can be seen in Figure 26.  
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PROTEIN ASSAY  
The protein assay was performed, as explained in the materials and methods section, on each 
COPYCAT immediately prior to digestion to minimise error. The protein assay relies on a very 
similar principle to densitometry, it is performed on the intact protein and the absorbance of a 
BSA standard, stained with Coomassie PlusTM protein assay reagent, is compared to the 
absorbance of a COPYCAT sample (Figure 26). 
A recent application note released by Amersham Biosciences (Application Note #6 
ImageMaster® VDS 80-6383-43) highlighted a key point to consider in the reliability of 
densitometry. The optical density of a Coomassie stained protein band on a gel was plotted 
against the concentration of that protein in the band, for two different proteins – Aldolase 
and GPDH. Their results indicate that the slope of the line of best fit for these two proteins 
was markedly different. This calls into question the reliability of a densitometry assay if the 
BSA standard used has a different slope of optical density/protein concentration to the 
analyte protein. A similar principle can also be considered concerning the reliability of the 
protein assay. The Coomassie dye used for protein assays is known to bind only selected 
amino acids at specific sites, if the number of these sites is not the same for the standard and 
analyte protein it stands to reason that the staining of the proteins will be different. Congdon 
et. al. showed that different proteins stained with Coomassie in a protein assay had different 
absorbances (Congdon et al., 1993) and this calls into question the reliability of the 
quantification from a protein assay. 
QUANTIFICATION USING THE GLUFIB PEPTIDE  
For quantification using the GluFib peptide, with either MALDI-TOF or Q-TOF MS, digests of 
each COPYCAT were used. Ordinarily in our lab unlabelled (light) GluFib is used, in a known 
amount, to quantify a labelled (heavy) QconCAT. In this case the COPYCAT is light, therefore it 
needs to be quantified with heavy GluFib. Accurately quantified heavy GluFib peptide was not 
available as a stand-alone reagent, therefore the quantification needed to involve two steps. 
First heavy CC002 was made and quantified using light GluFib. The heavy CC002 was then used 
as a source of heavy GluFib, in a known amount, to quantify the light COPYCATs.  
Each light COPYCAT was digested individually, the heavy CC002 was digested under two 
different conditions – one with light GluFib spiked into the digest mix (“heavy with” (HW)) and 
one without light GluFib in the digest (“heavy only” (HO)). The two heavy digests were 
performed in order to assess whether the quantification was affected by the stage at which 
the GluFib was added to the analysis; with the HW digest the GluFib is already present and the 
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sample can be directly analysed with MS to quantify the COPYCAT, with HO the GluFib needs 
to be spiked into the digest after digestion is complete, prior to MS analysis. This later stage of 
introduction could introduce more variance to the quantification.  
There is also a second aspect when considering which heavy digest to use – with HO the only 
GluFib present in the digest is heavy, therefore when the heavy is spiked in with a light 
COPYCAT for quantification there can be a direct comparison drawn between the heavy and 
light GluFib peaks. However with HW there is already light GluFib present in the digest, it is at 
a known amount so the quantification of the light COPYCAT can be adjusted accordingly but 
the presence of this extra GluFib could affect the quantification accuracy.  
The two heavy digests were analysed individually; HO was first spiked with a known amount of 
GluFib for quantification. Each light COPYCAT digest was quantified twice, once with HO and 
once with HW using MALDI-TOF MS and ESI-Q-TOF MS, an average of the resulting light 
COPYCAT quantification values was taken as the HO and HW were found to give very similar 
quantifications. The quantification was performed using MassLynx software to give an extract 
ion chromatogram for the GluFib peaks. To first quantify the heavy CC002 digests the peak 
areas for the light and heavy GluFib in the samples were calculated and the resulting values 
compared in a ratio which was then used to calculate the fmol of heavy GluFib in the sample 
from the known amount of light GluFib. Once the amount of heavy GluFib was known this was 
used to quantify the 10 light COPYCATs. So that the quantification values can all be compared 
against the protein assay and densitometry, where the amount of COPYCAT in the original 
undigested aliquot is quantified, the GluFib quantifications were then calculated back to give a 
final value for pmol/μl concentration of COPYCAT in the original aliquot. The resulting 
quantifications can be seen in Figure 26. 
At this stage of the assessment the methods were compared to judge how well they 
correlated. Figure 24 shows the alignment between the different quantification methods so 
far.  
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Visually the MALDI-TOF and ESI-Q-TOF quantifications correlate better than the others with 
the data points distributed close to the lines of best fit. This is to be expected as the only 
difference here is the instrumentation, the method of quantification is still the same. Table 6 
below shows the Pearson’s-r values from each graph:  
Y Axis pmol/ul value X Axis pmol/ul value Pearson's r 
Protein assay Densitometry 0.82528 
ESI-Q-TOF average Densitometry 0.73251 
MALDI-TOF average Densitometry 0.59659 
ESI-Q-TOF average Protein assay 0.75239 
MALDI-TOF average Protein assay 0.62927 
MALDI-TOF average ESI-Q-TOF average 0.96214 
Table 6| Pearson’s r values for comparisons between quantification method results  
Looking at the values above there seems to be good correlation between the densitometry 
and the protein assay quantification values, this again is to be expected as both methods use a 
similar principle of measuring the staining of the intact protein and comparing it to a standard 
to acquire the quantification value. There is worsening correlation between the two MS GluFib 
based quantifications and the intact protein quantifications, with the worst correlation 
between MALDI-TOF and Densitometry.  However the degree of correlation is still no 
indication as to which method provides the most accurate quantification.  
The MS quantifications are only accurate if the GluFib quantification peptide is released from 
the COPYCAT entirely. If there is a miss-cleavage either side of the GluFib peptide then a 
reduced level of peptide will be available for quantification and this will bias the results. To 
assess this a time course digest was performed on three COPYCATs (all used in the 10 light 
study) these three COPYCATs are stable isotope labelled to facilitate the use of unlabelled 
GluFib to monitor the release of the heavy GluFib peptide from the COPYCAT.  
The three COPYCATs chosen for the time-course were CC042, CC053 and CC060. Two digest 
conditions were set up for each, the first contained the COPYCAT plus 107.5fmol/ul 
concentration light GluFib and a yeast background. The second contained the same amount of 
COPYCAT and GluFib but no yeast. The two conditions were chosen to see if the complex yeast 
background affected the digestion efficiency. The digests were reduced with DTT and blocked 
with IAM before adding the trypsin. Time points were taken at 1 min, 2 min 5 min, 10 min, 15 
min, 30min, 60min, 120min, 240min and a final overnight time point. For each time point a 
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10μl sample was pipetted into 10μl of TFA, 1% final concentration, and placed on ice to stop 
digestion. The light GluFib is already present in each sample as it was added in the digest mix, 
meaning that the amount of light GluFib is constant for each sample. The time points were 
analysed using LC-ESI-Q-TOF MS. The peak areas for the heavy and light GluFib were extracted 
for each time point in each digest and the ratio between the two values calculated.  
Plots of the changing ratios over time reveal that the QconCATs have very different digestion 
profiles (Figure 25). Additionally for each COPYCAT the behaviour is different dependant on 
whether the digest is performed in a yeast background. For CC042 the digestions profiles are 
very similar with or without the background however digestion does seem to be slightly faster 
without the yeast present. In the sequence context there is an acidic residue in the P1’ 
location which could affect digestion and lead to a miss-cleave at that site however it does not 
seem to have affected digestion in this case. Neither of the two other sequence contexts for 
053 and 060 indicate a problematic digestion site. The difference between digestion efficiency 
in the two conditions is most apparent for CC053 where digestion with the yeast background 
is significantly slower than without. However both digests do eventually reach the same end 
point. For CC060 we see a very rapid release of the GluFib peptide without the background 
and again a slower release with yeast present. For this plot the two digests do not reach the 
same ratio end point. The final ratio for the yeast-background digest is higher. Looking at the 
curve of the lines for CC060 the digest without yeast plateaus after approximately 120min and 
the ratio at the plateau is lower than the highest ratio achieved by the background digest at 
240min. This might suggest that although the digest with yeast background is slower, more 
GluFib is released compared to the non-yeast digest. The difference in digestion profiles 
cannot be explained through the sequence context of the GluFib peptide. It is possible that 
another peptide released from the QconCAT is inhibiting the performance of the trypsin but 
there is no clear reason why this would affect the digest in yeast background more than 
without the background (CC053). 
For CC042 the ratio of heavy CC/light standard reached 12, for CC052 and CC060 the 
maximum ratios seen were 4 and 4.5 respectively (Figure 25). The difference in maximum 
ratio seen can be explained by the fact that CC042 was prepared differently to CC052 and 
CC060 prior to digestion. CC042 was prepared for digestion using NiMAC purification whereas 
CC053 and CC060 were RapiGest solubilised, the difference in the two preparation methods 
will result in differing concentrations of prepared COPYCAT solution; the COPYCATs were not 
diluted prior to the time course digestion so the starting concentration of each COPYCAT will 
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have varied. The same concentration of light GluFib was used for all digests however, meaning 
that the concentration of heavy COPYCAT, and therefore heavy GluFib, varied in relation to 
the light GluFib for each COPYCAT and this explains the differences seen in the final H/L ratios.  
In addition to the time course digests I also looked for missed cleavages around the GluFib 
peptide for each COPYCAT. I did this in two ways, I looked for any missed cleaves that were 
picked up in PLGS and I also viewed extracted ion chromatograms to look for the m/z for the 
sequence of the first sacrificial peptide coupled to GluFib - MAGREGVNDNEEGFFSAR. I could 
not find clear evidence of any missed cleaves in any of my 10 light COPYCAT digests from 
either method.  
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LABEL-FREE QUANTIFICATION 
The final method used for trial quantification of the COPYCATs was label-free quantification. 
For this it was decided that samples of each COPYCAT digest would be run at the same 
concentration. In order to do this it first needed to be decided which previous quantification 
value to use to calculate the dilutions required for each COPYCAT digest. As label-free 
quantification is an MS based approach it was decided that the other MS based quantification 
values would be most appropriate to use as a basis for dilutions. An average was taken of all 
of the GluFib quantification values (ESI-Q-TOF and MALDI-TOF MS data); these values were 
used to calculate dilutions for each COPYCAT digest. The samples were analysed using ESI-Q-
TOF (Synapt G1), samples of each digest were run twice – once individually and once in a ratio 
of 1:1:1:1:1:1:1:1:1:1 mix with each other. The digests were diluted to 500fmol/μl 
concentration, the 10 COPYCATs were mixed equally and then an equal volume of 50fmol/μl 
Phosphorylase B (PhosB) was added as the standard. Sample (2μl) was injected onto the 
column to give, what should be, 50fmol of each COPYCAT on column and 50fmol of PhosB. 
Each COPYCAT digest was also diluted further to give 50fmol/μl concentration of each 
individually and, after mixing 1:1 with 50fmol/μl PhosB, 2μl was injected of each onto the 
column. The data was processed using the label-free quantification method in PLGS. The 
values given for fmol on column from the label-free quantification were calculated back to 
give a final value of pmol/ul in the original undigested COPYCAT aliquot (Figure 26). 
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Figure 26 | Quantification values for the 10 COPYCATs. (a). The quantification values 
obtained for pmol/μl in original aliquot of each QconCAT, using 8 different methods, plotted 
as a column chart showing each individually. (b). The mean pmol/μl value for each QconCAT 
taking an average of the 8 different quantification methods, error bars showing the standard 
error for each mean.  
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The error bars for the average quantification values, for CC001 and CC002 particularly, reflect 
the variability in quantification values for the COPYCATs (Figure 26 (b)). This was expected 
given the range of values seen in Figure 26 (a). The label free quantification values tend to give 
higher pmol/μl concentrations than other methods (Figure 26 (a)). It can also be seen that the 
label free quantification when the COPYCATs are run individually gives a higher value than 
when the COPYCATs are analysed in a 1:1 mix. The reason for this difference was investigated 
and it was observed that the peptides selected as the top3 for quantification were not the 
same for the individual and the mix. This might suggest that the peptides ionise differently 
depending on the digest background,  however further study and an increased number of 
technical replicates is necessary to analyse this further.  As explained previously PLGS uses the 
“top3” rule to quantify proteins based on a comparison between the intensity of the top three 
peptides for a standard of known amount and the top 3 intensities for the analyte peptide. 
This method of quantification was developed using naturally occurring proteins as the analyte 
proteins. One explanation for the unusual quantification values given by the label-free analysis 
could be that the QconCAT peptides do not show the “normal” behaviour seen in naturally 
occurring proteins. These 10 COPYCATs were picked for this study because they are well 
characterised proteins containing specifically selected peptides, chosen by virtue of their 
reliable behaviour in a mass spectrometer. It could be that in selecting well behaved peptides 
for these proteins we have unconsciously increased the intensity of the “top3”, giving bias to 
the quantification.  
Given the above theory a brief comparison between the amino acid composition of the 
S.cerevisiae proteome and the amino acid composition of our current set of COPYCATs was 
performed (Figure 27). Some amino acids such as Leucine and Threonine are equally 
represented in the yeast and COPYCAT proteins, however there are several amino acids where 
there is a difference between the two protein groups. The greatest difference calculated was 
for methionine where there was an 86.97% drop in occurrence in the COPYCAT proteins 
compared to the yeast proteome. The average difference between the percentage occurrence 
of an amino acid in the yeast proteome and the percentage occurrence of an amino acid in a 
COPYCAT is 20%. This difference could be significant and could contribute to why label-free 
quantification of QconCATs may not be suitable.  
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The difference in average amino acid composition of COPYCATs compared to naturally 
occurring S.cerevisiae proteins could mean that the ionisation of COPYCAT peptides does not 
follow the same pattern as naturally occurring proteins, this could affect the reliability of label 
free quantification. The intensities of the top3 peptides chosen for the 10 light COPYCAT label 
free quantifications were compared to the intensities of the top3 peptides selected for label 
free quantification of 10 abundant S.cerevisiae proteins. The COPYCAT intensity values were 
taken from PLGS processing for the mix of COPYCATs; the mix was chosen as the S.cerevisiae 
for comparison was analysed in a complex background so the more complex sample was 
compared. The S.cerevisiae intensity values are taken from PLGS processing of a label free 
analysis of a S.cerevisiae whole cell lysate digest sample; the proteins listed as the 10 most 
abundant were selected. Two comparisons were made; first individual peptide intensities for 
the top 1, 2, and 3 were plotted for COPYCAT and S.cerevisiae, and secondly the average 
intensity for each of the top3 peptides for COPYCAT and S.cerevisiae were plotted for 
comparison (Figure 28). Comparing the top3 intensity distributions for each protein, the 
spread of curves in graphs (a) and (b) indicate that peptide ionisation behaviour varies greatly 
from protein to protein; variation appears to be present for both COPYCAT and S.cerevisiae 
proteins. The graph (c) suggests that for peptides 2 and 3 the percentage intensity is lower for 
COPYCAT proteins than for S.cerevisiae proteins. This does suggest a difference in behaviour 
between the COPYCAT proteins and the naturally occurring S.cerevisiae proteins, however this 
was not as originally anticipated. The label free quantification values for the COPYCATs were 
higher than the other quantification methods, in the majority of cases (Figure 26 (a)), and so it 
was suggested that the intensities of the top3 peptides chosen may be higher, on average, 
than for naturally occurring proteins. The results here show the converse and therefore do not 
explain the higher label free quantification values for the COPYCATs.  
An absorbance assay (A280nm) was considered for quantification of the QconCAT proteins, 
however the accuracy of the assay can vary widely depending on the accuracy of the 
estimated molar absorption coefficient for the protein (Pace et al., 1995), which varies 
depending on the number of aromatic residues and cysteines, in the sequence. The amino 
acid composition analysis revealed that the composition of QconCATs is very different from 
the yeast proteome, and specifically the aromatic residues tryptophan and tyrosine, are 
present in significantly lower amounts in the COPYCATs compared to the yeast proteome 
(39.68% and 11.26% differences respectively). This is likely to affect the accuracy of the assay 
and for this reason it was not used.  
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SUMMARY 
This work highlights the dependence of quantification on the method chosen for 
quantification of the standards. The wide range of values obtained here presents a common 
problem of deciding which method is the most accurate to give a reliable figure. Densitometry 
gives a visual result, contaminant proteins are immediately visible from the SDS-PAGE analysis 
giving more certainty to the fact that just the target protein is quantified; however the 
possible variation in staining makes the method unreliable. Protein assay works on a similar 
principle to densitometry and has the added disadvantage of not being able to assess any 
contaminants during the assay. With the previously mentioned potential for inaccuracy with 
label free quantification, in my opinion, quantification of the QconCAT using the GluFib 
peptide is the most reliable. GluFib has two major advantages over other methods. The first is 
that, like densitometry, contaminant proteins cannot interfere with the analysis as only GluFib 
heavy and light peptides are targeted. The second advantage is that, unlike any other method, 
the standard used to quantify the QconCAT resembles the QconCAT GluFib as closely as 
possible; a direct comparison is drawn between the heavy and light counterparts, there is no 
potential for differential behaviour due to the fact that, except for the m/z, the peptides 
behave identically in a mass spectrometer. I consider this similarity between standard and 
analyte to be of key importance to the accuracy of quantification. Amino acid analysis has 
been suggested as the gold standard for quantification of protein and this method could be 
used to compare to the other quantification methods and assess which aligns best with the 
amino acid analysis values.  
 
4.7 QconCATs to assess instrument performance 
Ideally to assess instrument performance the 10 COPYCATs would be combined in a dynamic 
range and this mixture used to assess instrument performance both in detection and 
quantification. The unexpected issue highlighted by the difficulty in standard quantification 
presents a problem in selecting a reliable quantification method. If the quantification of each 
COPYCAT is unreliable, we cannot be certain that the COPYCATs are in the correct ratio to 
create the dynamic range. We could take an average of the values and then simply take it on 
face value that the COPYCATs are present at the given amounts. MS performance could then 
be assessed by the ability to detect each COPYCAT to a suitable level of coverage. Hitting a 
certain level of coverage for each COPYCAT could be used as a quality control measure and 
comparisons could be drawn between the coverage obtained on different instruments to 
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assess instrument-to-instrument or lab-to-lab consistency. However a quality control tool that 
assesses quantitative as well as qualitative performance would be much more useful given the 
current trend in proteomics towards quantitative studies.  
There are a number of potential studies that could be conducted further to this work. A 
particular study I would have liked to have looked at would have been to assess whether the 
outcomes of the quantification studies would have been the same had naturally occurring 
proteins been used rather than the artificial QconCAT proteins. Recombinant proteins could 
be synthesised with two additional peptides – a HisTag for purification and peptide for 
quantification. They could therefore be purified and quantified in much the same way as the 
COPYCATs. However, in contrast to COPYCATs, the rest of the protein would be the same as 
the naturally occurring protein so may perform better with label-free quantification, this may 
mean that quantitative as well as qualitative MS performance parameters could be assessed 
on the instrument.   
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5. Conclusions 
The primary aim of this work was to shorten the QconCAT production process in terms of the 
number of days taken for QconCAT production, and also to streamline the production process 
making it simpler and applicable to multiplexing. The overall aim was to make it a more time 
efficient and accessible technology. I have discussed the processes which led to changes in the 
protocol, and how they have been implemented. The flow diagram in Figure 29 recapitulates 
the Figure 7 for the Aims and objectives section and summarises the areas where the protocol 
has been altered.  
I first addressed the cell culture and expression section of the protocol and reduced 
production time by removing the re-streaking of E.coli colonies on agar plates; this reduced 
the protocol by 1d. Secondly by eliminating the trial unlabelled culture the protocol was 
shortened, expressing the QconCAT in a “straight-to-heavy” approach reduced the production 
time by 5d.  The reason for the straight to heavy approach was that we have never seen 
evidence for an incorrect QconCAT being synthesised, QconCATs are produced reliably and 
consistently as shown in this thesis. Repeated expression of QconCATs has lead to a greater 
understanding of the behaviour of these proteins; wide variability in expression levels has 
been observed and this impacts on the further processing of the protein. The consistent 
expression of the correct QconCAT construct lead to removal of the verification step, 
verification of the QconCAT is now delayed until after the final labelled QconCAT is produced. 
Removal of the early verification step reduced the production time by 6d.  
I set out to investigate alternative methods of E.coli cell lysis and protein purification and to 
establish whether more rapid methods were available. The use of sonication rather than 
BugBusting for cell lysis has removed 0.5d from the protocol. Sonication also allows for 
multiple cell pellets to be sonicated in a short period of time therefore facilitating multiplexing 
of this step in the protocol. Alternative methods of QconCAT protein purification were 
investigated and ultimately the purification of the QconCAT protein was eliminated for 
adequately expressing QconCATs, replaced by simple solubilisation. RapiGest solubilisation is 
now used in place of purification; the unpurified inclusion bodies are quickly solubilised in a 
reagent which is compatible with protein digestion and mass spectrometric analysis. 
Removing the purification step reduces the production time scale by 1d. RapiGest 
solubilisation is also easily multiplexed. Overall the improvements to the QconCAT production 
protocol has reduced the time scale for preparation of the protein by 13.5d. The actual time 
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gains are greater than this as the improved protocol facilitates multiplexing, routinely 8 
QconCATs are synthesised in parallel.  
The final study of 10 QconCATs highlighted the difficulty in quantifying a standard. There were 
a number of different methods used for quantification; each method produced significantly 
different values. Every quantification method had merits and demerits and there is a 
significant difficulty in selecting the “correct” value in order to proceed. It was discussed that 
GluFib peptide based quantification may be the more reliable quantification method but that 
amino acid analysis should be considered for a gold standard quantification value. A potential 
further study was outlined to assess the behaviour of naturally occurring proteins in the same 
workflow.   
The QconCAT production protocol has been adapted for use as a high throughput, multiplexed 
technique applicable to large scale quantification studies. However the applications of 
QconCATs reach beyond label-mediated quantification and this aspect of their use has yet to 
be fully explored.  
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